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THE ROLE OF METNASE IN DNA REPLICATION FORK STRESS RESPONSE
AND DNA REPAIR

Leyma Pérez De Haro
B.S., Biochemistry, California State University, Los Angeles, 2004

ABSTRACT

Metnase is a recently evolved human protein with methylase (SET) and
nuclease domains that is widely expressed, especially in proliferating tissues.
Metnase promotes plasmid and viral DNA integration, and through an interaction
with topoisomerase IIα (TopoIIα) it promotes chromosome decatenation.
Metnase interacts with DNA ligase IV, promotes non-homologous end-joining
(NHEJ), and repression causes mild hypersensitivity to ionizing radiation.
TopoIIα has a proposed role in relaxing positive supercoils in front of replication
forks. NHEJ factors have been implicated in the replication stress response.
Here we show that Metnase promotes cell proliferation, but does not affect
replication fork elongation as measured by cell cycle analysis, BrdU
incorporation and DNA fiber analysis. Even though there is no elongation effect,
Metnase confers resistance to three replication stress agents, hydroxyurea, UV
light, and the topoisomerase I inhibitor, camptothecin. Metnase expression also
increases the rate at which H2AX phosphorylation (a marker of stalled or
collapsed replication forks) is resolved. There was no difference in formation of
gamma-H2AX

foci

after

exposure

to

these

agents.

Metnase

co-

immunoprecipitates (co-IP) with proliferating cell nuclear antigen (PCNA) and
vi

RAD9. Finally, we show that Metnase promotes TopoIIα-mediated relaxation of
positively supercoiled DNA, similar to the torsional strain preceding replication
forks. These results establish Metnase as an important component of the human
replication stress response.
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1. INTRODUCTION
1.1. Cancer epidemiology
Cancer is an important public health concern in the United States, where
one out of every four deaths is due to cancer [1-5]. It has been estimated that
during 2009 there will be approximately 1.5 million new cancer cases diagnosed,
and about 560,000 deaths due to cancer. Recently, the incidence of cancer has
decreased at a yearly rate of 1.8% in males and 0.6% in females. This is largely
attributed to better screening for the three major sites of cancer in men (lung,
prostate, and colorectal) and the two major sites in women (breast and
colorectal). However, the probability of a person being diagnosed with cancer in
a lifetime is 44% for men and 37% for women [1]. Additionally, cancer is the
second leading cause of all deaths in children 1-14 years of age (as of 2006),
with acute lymphoblastic leukemia (ALL) being the most common type.
However, the five year cancer survival rates have increased from 58% in 1977 to
80% in 2004 in children, and in adults the survival rate is ~90% for some types
of cancers, with many exceptions such as pancreatic cancer, some forms of
brain tumors, and advanced stages of metastatic cancer [1]. Although there have
been many improvements in cancer detection, diagnosis, treatment, and survival
over the past few decades. Cancer is nevertheless the second leading cause of
all deaths in the US (as of 2006) [1, 6]. Therefore, the study of the molecular
basis of cancer is important, and the understanding of the events leading up to
the transformation of a normal cell into a cancerous one, imperative.
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1.2. Genomic instability and cancer
In 1890, David von Hansemann postulated that aberrant mitotic events
were responsible for the abnormal chromosomal content found in cancer cells
[7]. In 1914, Theodor Boveri explored this hypothesis in sea urchin eggs, and
demonstrated that aberrant mitosis led to unequal distributions of chromosomes,
which he postulated would lead to malignant cells with the ability of “unlimited
growth”, and that these malignant cells could pass on this information to the next
generation of daughter cells [7]. Additionally, Boveri accurately predicted the
existence of cell-cycle checkpoints, oncogenes, and tumor suppressor genes.
He envisioned that “poisons”, such as radiation and nicotine, could affect mitosis
and create chromosomal imbalances in cells [7]. These two scientists formulated
the idea that cancer is a genetic disease. Later, work by Schimke provided the
first evidence that cancer cells amplified drug resistance genes, and that
treatment made cells genetically unstable [8]. Thus, the link between genomic
instability and cancer has been established.

1.3. DNA repair
Boveri initiated the idea that cancer can arise from defects in DNA repair
mechanisms that protect cells from damage [9]. In seminal work, Alfred Knudson
postulated that retinoblastoma arises from two genetic mutations in each allele
of the retinoblastoma (Rb) gene [10]. Nordling had concluded earlier that seven
mutations fit the range of most cancers [11]. Nordling’s observation still holds
today. Importantly, genes associated with cancer such as p53 and Rb were
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shown either to be regulated by, or to regulate the cell cycle, and it was
demonstrated that p53 is a moderator of the DNA-damage checkpoint [12-16].
Finally, in the 1990s, a clear link was established between several DNA repair
pathways, such as nucleotide excision repair (NER), mismatch repair (MMR),
and homologous recombination (HR) proteins, and cancer pre-disposition
disorders, such as xeroderma pigmentosum (XP), hereditary non-polyposis
colon cancer (HNPCC), and familial breast cancer, respectively [9]. This work
exploded with the discovery of many more factors involved in DNA repair, cell
cycle regulation, and DNA replication, many of which are linked to cancer
development or cancer predisposition disorders.
This dissertation focuses specifically on the study of a protein involved in
the repair of DNA double-strand breaks, processing of DNA double-strand ends
(DSEs), and re-starting stopped or collapsed DNA replication forks. The proper
function of DNA repair pathways is necessary for cell viability and for prevention
of transformation into cancer. Here are described studies of Metnase, a DNA
repair protein with important roles in non-homologous end-joining, DNA
integration, and chromosomal decatenation, and its novel role in DNA replication
in response to stress. Additionally, two novel interactions between Metnase and
the DNA replication proteins, PCNA and Rad9, are identified. This work
demonstrates that Metnase is a key component in pathways important for
genomic instability.

3

2. BACKGROUND
2.1. DNA damage
DNA double-strand breaks (DSBs) and DNA double-stranded ends
(DSEs) can be seriously damaging to cells, affecting their viability and genome
stability. DSBs and DSEs are normally generated during DNA replication, when
a replication fork encounters DNA blocking lesions. These lesions are produced
by metabolic byproducts of cellular respiration (reactive oxygen species; ROS)
which could lead to fork collapse [17]. They can also occur during programmed
genome rearrangements induced by nucleases, including yeast mating-type
switching [18], V(D)J recombination [19], class-switch recombination [20], and
meiosis [21]; and from physical stress when catenated chromosomes are pulled
to opposite poles during mitosis [22]. DSBs are also produced when cells are
exposed to exogenous DNA damaging agents such as ionizing radiation (IR),
which creates DSBs both by direct energy absorption, and indirectly via
production of ROS [23]; chemical agents and ultraviolet (UV) light that create
replication blocking lesions (alkyl adducts, pyrimidine dimmers, and crosslinks)
[24, 25]; and cancer chemotherapeutics that poison topoisomerase I and II,
which produce replication-blocking lesions, or which trap the enzyme-DNA
complex after DSB induction and can potentially produce DSBs during any
phase of the cell cycle [26]. Misrepair, or the failure to repair DSBs, can result in
cell death or large-scale chromosome changes that are hallmarks of cancer
cells, including deletions, translocations, and chromosome fusions that enhance
genome instability.

Cells have evolved groups of proteins that function in
4

signaling networks that sense DSBs or other DNA damage, arrest the cell cycle,
and activate DNA repair pathways.

These cellular responses can occur at

various stages of the cell cycle and are collectively called DNA damage
checkpoints. However, when cells suffer damage beyond their ability to repair,
signaling pathways can trigger apoptosis and prevent the propagation of cells
with highly unstable genomes [27].

2.2. Sources of endogenous double-strand breaks
DSBs arise spontaneously during normal DNA metabolism, including DNA
replication and repair, and during programmed genome rearrangements, such as
immune cell V(D)J recombination. Many DNA lesions block DNA polymerase,
causing replication fork stalling. Stalled forks are stabilized by many factors
including the checkpoint kinases ATM and ATR, the DNA repair protein BLM,
and the multifunctional single-strand DNA binding protein RPA [28]. In addition,
Topoisomerase IIα (TopoIIα) creates DSBs as part of its normal function, and
passes double-stranded DNA through the break, decatenating tangled
chromosomes before mitosis. If decatenation fails, DSBs may form when
catenated chromosomes are pulled toward opposite spindle poles [29].
Endogenous DSBs are also formed during lymphoid development, in B-cells,
where V(D)J recombination is initiated by specific DSBs introduced into
recombination

signal

sequences

(RSS)

sequences

by

the

RAG1/2

endonucleases; these DSBs are subsequently repaired by an error-prone,
NHEJ-mediated deletion mechanism that creates novel V(D)J junctions in
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antibody coding sequences, a process that is instrumental in generating
antibody diversity in mammals [30].

2.3. Sources of exogenous DNA double-strand breaks
DSBs are produced by a wide variety of exogenous DNA damaging
agents. Ionizing radiation (IR), including X-rays, γ-rays, β-particles, and α
particles, can cause many types of DNA damage. The vast majority of the
cytotoxicity associated with IR is due to DSBs. DSBs can also be caused by
radiomimetic drugs such as the TopoIIα inhibitors etoposide and adriamycin.
TopoIIα is inhibited by the anthracyclines and etoposide, all of which are used in
cancer

chemotherapy

[31].

Topo-II

inhibitors

induce

ATM

Ser-1981

phosphorylation and phosphorylation of histone H2AX (γH2AX), both hallmarks
of DSB damage [32]. Tobacco smoke is a known carcinogen that induces
mutations and DSBs [33]; this damage is mediated through free radicals and is
dose dependent [34]. Thus, cells experience many DSBs daily, coming from
external and internal sources, which require the proper sensing and repair in
order to avoid cell death or genomic instability leading to cancer.

2.4. Syndromes resulting from deficient DNA repair
A key link between DNA repair defects and cancer is the existence of
syndromes that have been linked to numerous DNA repair proteins. In humans,
mutations in the proteins responsible for DSB repair generate syndromes
resulting

in

a

predisposition

to

cancers,
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mental

retardation

and

neurodegenerative disorders. The syndromes identified so far are: Bloom’s
Syndrome

(BLM

protein),

Werner’s

Syndrome

(WRN

protein),

Ataxia-

Telangiectasia (ATM protein), Seckel syndrome (ATR protein), Cockayne
syndrome (CSA and CSB proteins), Li-Fraumeni syndrome (p53 protein),
hereditary non-polyposis colon cancer (mismatch repair proteins), Nijmegen
Breakage Syndrome (Nbs1 protein), inherited breast cancer (BRCA1 and 2
proteins), Fanconi’s Anemia (FA proteins), and Ligase IV syndrome which
results in cancer predisposition in people deficient in the proteins Artemis and
LigIV (see Table 2-1 for references).
Bloom’s Syndrome results from mutations in genes that code for a protein
homologous to the E. coli RecQ 3’-5’ helicase [38]. This syndrome is a rare
autosomal

recessive

disorder

characterized

by

telangiectases

and

photosensitivity, growth deficiency, variable degrees of immunodeficiency, and
cancer predisposition [39]. Bloom’s Syndrome cells in culture are markedly
sensitive to HU and UV, but not IR [40, 41]. These studies firmly implicate the
Bloom’s syndrome protein BLM in replication-associated DSB repair. BLM has
recently been demonstrated to play a role in the processing of Holliday
Junctions (HJ) resulting from stalled and collapsed replication forks. It has been
proposed that BLM associates with Topoisomerase III and functions as a
Holiday Junction (HJ) resolvase [42, 43].
Mutations that cause Werner’s syndrome occur in the protein WRN,
another RecQ family helicase that also possesses an ATP dependent 3’-5’
exonuclease motif [44-47]. WRN has the ability to branch migrate HJs during HR
7

and it has been shown to be important in telomere maintenance and cellular
senescence [48].
Ataxia-Telangiectasia has been shown to be the result of mutations in a
specific gene named AT-Mutated (ATM). AT is a rare disorder where patients
suffer from neurodegeneration, immunodeficiency, and cancer predisposition.
ATM is a serine/threonine kinase activated by DNA DSBs [35]. In undamaged
cells it is a homo-dimmer which undergoes autophosphorylation in the presence
of DNA DSBs [36]. Once phosphorylated on serine 1981, ATM is activated and
phosphorylates a number of important DNA repair factors including p53, Chk2,
BRCA1, RPAp34, H2AX, SMC1, FANCD2, RAD17, Artemis and Nbs1 [35]. ATM
functions as an upstream regulator of both NHEJ and HR [37].
Nijmegen Breakage Syndrome (NBS) is an autosomal recessive disorder
known to result from mutations in the protein named Nbs1. Nbs1 is part of a
heterotrimeric protein complex consisting of Mre11, Rad50 and Nbs1 (MRN),
which is conserved from yeast to mammals and functions in the identification
and signaling of DNA DSBs [49].

The MRN complex is important in the

activation of ATM, ATR, and the initiation of a proper DSB induced cellular
response.
Fanconi’s Anemia (FA) is an inherited syndrome where patients display
bone marrow failure, developmental abnormalities, and a severe predisposition
to cancer. FA consists of 13 complementation groups (FANCA, B, C, D1, D2, E,
F, G, I, J, L, and M) each of which represent a specific gene that has been
mutated or deleted [50]. FA cells are extremely sensitive to DNA crosslinking
8

drugs such as MMC and show altered phenotypes comprising abnormal cell
cycle regulation (extended G 2 ), hypersensitivity to oxygen, increased apoptosis,
and accelerated telomere shortening [51]. All known FA proteins have functions
in DNA repair pathways that are involved in the re-start of stalled replication
forks. The majority of these protein products have been shown to form a complex
that functions as the E3 specificity enzyme in mono-ubiquitination of FANCD2.
Ubiquitinated FANCD2 performs multiple tasks including the recruitment of
BRCA2, enhancement of HR, and possibly the promotion of translesion DNA
synthesis [52].

9

Table 2-1. Summary of DNA repair syndromes and the proteins affected.
Condition

Protein

Function

Reference

Familial breast cancer

BRCA1

Involved in HR and NHEJ

[53-55]

Familial breast cancer and Fanconi’s
anemia

BRCA2

Involved in HR, helps load
Rad51

[56-61]

Li-Fraumeni syndrome

p53

Associates with XRCC1

[62, 63]

Chk2

Phosphorylated by ATM,
activates downstream
factors involved in DSB
repair

[63-67]

ATM

Member of the PI3K family,
activates Chk2 and is
involved in the DNA DSB
response

[68-70]

ATR

Member of the PI3K family,
activates Chk1 and is
involved in the DNA
replication stress response
and the DNA DSB
response

[71, 72]

Nbs1

Member of the MRN
complex, involved in
sensing DBS and recruiting
repair proteins to the break
site

[73, 74]

WRN

ATP dependent
exonuclease, important for
HR and telomere
maintenance

[48, 75-90]

Bloom’s Syndrome

BLM

Important for repair of
stalled or collapsed
replication forks and
Holiday Junction (HJ)
resolution

[42, 43, 9199]

Fanconi’s Anemia

FANC A, B,
C, D1 & 2,
E, F, G, I,
J, L, M

Involved in DNA repair and
re-start of stalled replication
forks

[100-110]

Li-Fraumeni syndrome

Ataxia Telangiectasia (AT)

Seckel Syndrome (SCLK)

Nijmegen breakage syndrome (NBS)

Werner Syndrome

10

2.5. DNA double-strand break damage repair in eukaryotic cells
Eukaryotic cells repair DSBs by two mechanisms:

homologous

recombination (HR) and non-homologous end-joining (NHEJ). Both pathways
are able to repair frank DSBs, such as those produced by nucleases and IR.
DSBs produced by replication fork collapse are repaired primarily by HR [111,
112]; however there is an emerging body of literature that points to NHEJ also
having a role in this repair (discussed in more detail later).

Fork collapse

produces a one-ended DSB, better described as a “double-strand end” (DSE).
Because a DSE at a collapsed fork has no second end with which to rejoin, it
has been difficult to imagine how NHEJ can contribute to the repair of collapsed
replication forks, although this does not rule out indirect roles for NHEJ proteins
in replication fork restart. For a detailed review of the control of pathway choice
between HR and NHEJ ( see Appendix 6.1) [37].

2.5.1. DNA damage and replication
DNA replication is a process that makes cells particularly vulnerable to
DNA damage because many DNA lesions cause replication forks to stall.
Cellular responses to replication stress are extremely important in cancer
therapy, as a number of chemotherapeutic drugs target DNA metabolism and
cause replication stress, including topoisomerase poisons camptothecin (CPT)
and hydroxyurea (HU). Cells deal with stalled replication forks in several ways:
1) single-stranded DNA (ssDNA) bound by RPA accumulates at stalled forks and
is a major signal for downstream events including fork repair and checkpoint

11

activation (Table 2-2). 2) The replisome at stalled forks is stabilized by proteins
that function in DNA repair and the DNA damage checkpoint response, including
RPA, ATR-ATRIP, ATM, TOPBP1, Claspin, 9-1-1 complex, and MDC1 [113116]; the action of these proteins may preserve the fork structure while the
damage is repaired, allowing replication to resume. 3) Alternatively, error-prone
translesion synthesis (TLS) polymerases are recruited to monoubiquitinated
proliferating cell nuclear antigen (PCNA), allowing lesion bypass in a damage
tolerance pathway [117, 118].

Table 2-2. List of all three PIK kinases involved in the repair of DNA DSBs
and DNA replication fork damage.
Modified from [119].

Kinase

Target

Activator

Post-translational
modification regulation

ATM

Nbs1

Mre11/Rad50 and DNA
ends

Phosphorylation

ATR

ATRIP

TOPBP1 and DNA
damage

Phosphorylation

DNA-PKcs

Ku70/80

Ku70/80 and DNA ends

Phosphorylation
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Type I and type II topoisomerases are very important for normal DNA
replication.

Topoisomerase I (type I) plays a major role in relaxing positive

supercoils produced in front of replication forks during duplex DNA unwinding by
the replicative helicase. Topoisomerase IIα (TopoIIα), a type II topoisomerase that has
roles in chromosome condensation and decatenation, is present in the replisome, and it has
been proposed that it also relaxes positive supercoils ahead of replication forks [120-122].

Although it is known that topoisomerase poisons cause replication stress,
specific roles for topoisomerases in response to replication stress have not been
defined.
If stalled forks are not restarted in a timely manner, they may be
converted to unusual DNA structures and collapse, creating a DSE (see Figure
2-1). Certain types of damage, such as single-strand breaks, may cause direct
fork collapse to DSEs. As with double-strand breaks, the checkpoint kinases
ATM and ATR are recruited to DSEs and activated, leading to histone H2AX
phosphorylation (γ-H2AX) in the vicinity of DSEs [123].

This chromatin

modification is important for fork repair and checkpoint activation, and once
collapsed forks are repaired, γ-H2AX is replaced by unmodified H2AX [30, 124,
125].

Homologous recombination (HR), involving RAD51-mediated strand

invasion, plays a major role in restarting stalled and collapsed forks [115]. NHEJ
factors also play a role in cell survival after replication stress [126] (Figure 2-1).
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Figure 2-1. Replication fork re-start.
When a replication fork encounters a single stranded lesion cells may
take two routes to resolve the problem. The lesion may be bypassed via Chicken
foot formation or error-prone translesion synthesis (TLS). Alternatively, the
lesion may become a double stranded end (DSE) and be resolved via HR.
Although HR is currently believed to be the major repair mechanism for DSEs,
there is new evidence suggesting that NHEJ factors may also contribute to this
repair. Whether the HR and the NHEJ pathways are mutually exclusive or
overlapping remains to be elucidated.
14

Replication stress activates the intra-S checkpoint, which delays the rate
of replication fork progression in order to allow time for DNA repair [115].
ssDNA-RPA at stalled forks is bound by ATRIP leading to activation of its
obligate binding partner ATR. ATR activation depends on RAD17 (plus Rfc2-5)
loading of the RAD9-HUS1-RAD1 complex (9-1-1; a scaffold and processivity
factor structurally related to PCNA) through a RAD9-RPA interaction. RAD9
recruits TopBP1, an essential factor for ATR activation. ATR phosphorylates
RAD17,

which

recruits

Claspin

to

be

phosphorylated

by

ATR,

and

phosphorylated RAD17-Claspin promotes ATR phosphorylation/activation of
Chk1 kinase, which phosphorylates proteins that stabilize the stalled fork and
prevent late origin firing (Figures 2-2 and 2-3)
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Figure 2-2. Lesions that activate ATM and ATR at a replication fork.
A stalled replication fork activates ATR kinase, which then phosphorylates
and activates Chk1. However, nucleases present at the stalled fork can cleave
the DNA or the fork can collapse to a DSE. When this happens ATM kinase is
activated, and it activates the downstream substrate Chk2 via phosphorylation.
Both Chk1 and Chk2 play important roles in activating the cell cycle checkpoints
and recruiting DNA repair factors to the stalled/collapsed fork. Modified from
[119], star=phosphorylation.
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Figure 2-3. ATR mediated activation of cell cycle checkpoint and DNA
repair machinery in response to DNA replication fork damage.
When a replication fork encounters DNA damage, the PIK kinase ATR is
activated, and it phosphorylates Chk1. Chk1 phosphorylation activates its kinase
activity, which then phosphorylates other downstream substrates that negatively
regulate cell cycle and DNA replication origin firing. Adapted from [119],
star=phosphorylation.
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2.5.2. Role of HR in replication fork damage repair
Homologous recombination (HR) is the main repair pathway cells use to
repair replication fork damage. Usually a homologous sequence is required to
make a copy of damaged DNA; thus making this process more accurate than
NHEJ. The proteins involved in HR are Rad51 and its five paralogs (Rad51B,
Rad51C, Rad51D, XRCC2, and XRCC3), Rad52, Rad54, BRCA1 and 2, BLM,
WRN. Rad51 is the essential protein in this pathway and its absence results in
cell and embryonic lethality in mice [127]; which explains why there is no Rad51
cancer defect. However, defects in other HR proteins result in cancer
predisposition disorders and premature aging (see Table 2-1). BRCA1 and
BRCA2 mutations are particularly severe and result in familial breast cancer,
with approximately 60-85% chance of developing breast or ovarian cancer in
patients with the mutated proteins. A model of HR is depicted in figure 2-4, a
structure similar to those presented in figure 2-1 can be resolved by the Rasd51
coating of the DSE and subsequent invasion of a near-by homologous sequence
on the sister chromatid.
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Figure 2-4. Homologous recombination repair of DSBs.
A DSB caused by radiation or other sources mentioned in the text, is
recognized by the MRN complex, which regulates end resection from a 5’ to 3’
direction. This yields a single stranded DNA (ssDNA) section, which is bound by
RPA. Subsequently, Rad51 is loaded onto the ssDNA with the help of BRCA2,
producing a RAD51-ssDNA nucleoprotein filament that is able to search for
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homologous sequences elsewhere in the genome and catalyze strand invasion,
producing intermediates termed Holliday junctions. The invading strand can be
extended by new DNA synthesis using as a template the sister chromatid (shown
here in black). Finally, Holliday Junctions are resolved by helicases, nucleases,
and/or topoisomerases, resulting in mature products, and repair of the DSB.
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2.5.3. Role of NHEJ in replication fork damage repair
NHEJ is one of two DNA DSB repair pathways in mammalian cells. It is
the major repair pathway and plays a role throughout the cell cycle, but is
especially important during G 1 phase when sister chromatids are not available to
serve as HR repair templates. NHEJ repair factors are recruited to the DSB site
though the MRN, complex and in the classical (C-NHEJ) pathway. The Ku70/80
complex binds the free DNA ends, translocates away from broken ends, and this
permits DNA-PKcs to contact the DNA end, which then activates the
serine/threonine kinase activity of DNA-PKcs. This activation of the kinase
permits DNA-PKcs to autophosphorylate and causes a conformational change in
DNA-PKcs that enhances access by other NHEJ proteins [128]. Subsequently
XRCC4/LigIV ligates the two ends (Figure 2-5). Alternatively, PARP-1 has been
shown to compete with Ku for DNA ends and is thought to play a role in
alternative, or non-classical, NHEJ (A-NHEJ) pathway [129]. Other proteins such
as BLM are also thought to play a role in A-NHEJ during V(D)J recombination,
and Ligase3/XRCC1 have been shown to catalyze the ligation reaction in that
case, even though the other classical NHEJ factors may also be present [128]. It
is possible that the NHEJ pathway functions with much flexibility, so that different
factors are recruited depending on the cell cycle stage, cell type (or tissue), or
type of end. This would explain the observations stated above since some NHEJ
factors would be able to bind certain types of ends, while under different
conditions factor recruitment may differ.
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NHEJ factors been recently implicated in the repair of replication fork
damage. DNA-PK has been shown to be important in the repair of replication
fork damage, since cells lacking DNA-PK and treated with replication fork stress
had delayed replication [130]. In fission yeast it has been shown that Ku is
important in stalled replication forks and that this function is independent of its
NHEJ function [131]. A recently identified NHEJ gene, Cernunos/XLF, a gene
mutated in patients with microcephaly, has also been shown to be important in
replication. Cells lacking Cernunos and exposed to replication stress accumulate
in G 2 /M and have chromosomal instability. Importantly for this work are the
recent findings linking PARP-1, a protein believed to play a role in alternative
NHEJ, to replication fork progression. The Helleday laboratory used a DNA fiber
assay to show that cells lacking PARP-1 were unable to restart ongoing
replication forks, as compared to the control cells [132]. Additionally, the same
study showed that PARP-1 co-localized to replication fork-specific foci (labeled
with BrdU). Furthermore, they showed direct binding of PARP-1 to stalled
replication forks, thus identifying PARP-1 as an important factor in resolving
stalled forks. Helleday speculates that PARP-1’s function at stalled forks is to
stimulate HR repair. Alternatively, it could recruit A-NHEJ components to resolve
DSEs at collapsed forks.
Metnase is a novel NHEJ factor that interacts with XRCC4/LigIV and
stimulates the efficiency and accuracy of NHEJ (described in more detail later).
This dissertation presents evidence that Metnase also plays a role in replication
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fork re-start; thus placing it in the same category as the proteins mentioned
above.
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Figure 2-5. Non-homologous end joining of DSBs.
After a DSB is induced by IR or other sources explained in the text, the
MRN complex binds the DNA double stranded end (DSE) and initiates end
processing. In the classical NHEJ pathway, Ku70/80 binds the free DNA ends
and recruits DNA-PKcs. Ligase IV/XRCC4 associates with DNA-PK in a DNAindependent manner, which results in stimulated ligase activity. Subsequently,
DNA ligase IV/XRCC3 complex ligate the ends yielding a repaired product. In
the non-classical or alternative NHEJ pathway PARP-1, binds the DSE instead
of Ku70/80, and DNA ligase III/XRCC1 perform the ligation step. Both processes
are considered more error prone than HR because ends are resected to obtain
microhomology. This DNA end processing sometimes results in errors such as
small deletions.
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2.6. Metnase
2.6.1. Evolution of Metnase
Metnase was first identified as a chimeric mRNA transcript that consisted
of a SET and a nuclease domain [133]. The SET domain fused with the
transposase coding region of the mariner-like human mariner 1 (Hsmar1)
transposon, in-frame; resulting in a gene that contains three exons [133].
Cordaux and colleagues determined that first an Hsmar1 transposon was
inserted downstream of a SET gene. Then, the transposase domain of the gene
was incorporated 40-58 million years ago. Finally, a previously non-coding
sequence became an exon and in the process created de novo a new intron
[134]. Thus, the final functional gene is present only in higher primates (Figure
2-6). Furthermore, the Cordaux group studied the transposase domain and
determined that it contains a helix-turn-helix motif and a DDN motif, common in
mariner transposase domains. These qualities allow Metnase to bind DNA in
vitro, to the terminal inverted repeats (TIR) of the Hsmar1 gene [134]. They
estimated that there are about 1,500 nearly perfect Metnase binding sites in the
human genome [134]. Therefore, Metnase was determined to be a recently
evolved protein, containing three exons, and with the capacity to bind DNA in a
sequence specific manner.
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nuclease

Figure 2-6. Metnase is a 78 kDa protein.
Metnase contains a full SET (methylase) domain containing a pre-SET,
SET, and post-SET domains. It also contains a nuclease domain and a nuclear
localization sequence (NLS).

2.6.2. Metnase as a possible transposase
The work of Cordaux was followed by a detailed study from the Chalmers
group addressing Metnase as a potential human transposase [135]. They cloned
full length Metnase and exon3 (transposase domain) from human cDNA and
used it in an integration assay with the Hsmar1 transposon as the integration
element. The transposase domain of Metnase showed integration activity
through the DDN motif in a Mn2+ dependent manner. Although the integration
frequency was very low, it was comparable to V(D)J recombination transposition
activities of RAG1/2 [135, 136]. However, when they used a pre-cleaved Hsmar1
transposon, the integration efficiency increased by more than 100 fold, levels
comparable to other known transposases such as Mos1. This suggested that full
length Metnase and exon3 lacked the biochemical activities necessary for one or
more of the transposition reaction preceding the cleaved transposon element
integration step [135]. The formation of a paired-end-complex (PEC) is an early
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step in the DNA transposition reaction. Liu and colleagues demonstrated using
electrophoretic mobility shift assays (EMSA) that Metnase and exon 3 assemble
the PEC complex very efficiently, reaching 10% complex assembly, a level of
efficiency surpassing any previously established for other mariner transposases
[135]. The next step of the transposase reaction is the nicking of the 3’ end of
the transposable element, which generates a 3’ hydroxyl group at the end of the
element. Metnase exon 3 showed 3’ nicking activity as expected, but it also
nicked the 5’ end of the opposite strand, 3 bp within the element, and this latter
activity was much more efficient than the 3’ nicking. Thus, Metnase showed a
defect in this crucial step of the transposition reaction [135]. The final step of the
transposition reaction is the simultaneous integration of the 3’ ends of the
transposable element into a target site. Metnase and exon 3 were proficient in
this step in a Mn2+ dependent manner, and this observation was later confirmed
by a different group [137]. Further testing of the full length Metnase protein
demonstrated that Metnase contained all the in vitro activities observed with
exon 3 [135]. A study by Roman and colleagues confirmed the DNA binding and
nicking activities of Metnase and further implicated the helix-turn-helix (HTH)
motif for the interaction between Metnase and terminal inverted repeats (TIR),
and the DDN motif in the DNA cleavage reaction [138]. Taken together, their
observations demonstrate that although Metnase contains some important
biochemical activities of a transposase, it is largely deficient in the in vitro
transposase reaction and it is therefore not a true human transposase. However,
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the DNA binding and nicking activities could be important for other functions of
Metnase as described below.

2.6.3. Metnase promotes DNA integration
Metnase evolved from a transposase, which normally has DNA integration
activity. Therefore, the Hromas and Nickoloff laboratories investigated whether
Metnase could integrate viral DNA into the genome. Metnase integrates viral
and plasmid DNA into the genome [139, 140]. When Metnase was
overexpressed in human HEK-293 cells, the frequency of plasmid integration
increased significantly, in cis and trans [139]. Additionally, Metnase also
integrated Moloney leukemia virus (MLV) DNA into the same cells; suggesting
that Metnase also functions as a viral integrase [139]. Williamson and
colleagues later investigated whether Metnase functions to promote lentiviral
(HIV) integration, and demonstrated that protein expression correlates with
lentiviral integration [140]. Thus, Metnase is an integrase with the capacity to
integrate DNA, HIV and other retroviruses into the human genome. This is
important because Metnase could have roles in viral life cycles and infectivity,
but it is also of interest because it can be manipulated to improve the efficiency
of gene therapy.

2.6.4. Metnase expression and methylation activity
Our laboratory first characterized Metnase in 2005 and linked it to the
NHEJ DNA-DSB repair pathway [139]. In that study, Lee and colleagues cloned
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the Metnase gene from cDNA, sequenced the gene, and confirmed that it
expresses a full-length protein via Western blot analysis. Metnase contains a full
SET domain, including pre-SET and SET domains (Figure 2-6). Metnase was
shown to be expressed in all human tissues tested including brain, colon, heart,
leukocyte, liver, lung, ovary, placenta, prostate, skeletal muscle, intestine,
spleen, and thymus; with placenta having the highest and skeletal muscle the
lowest expression levels respectively [139]; suggesting that Metnase expression
correlates with proliferative tissues.
One of the most important findings from the Lee study was that Metnase
possesses in vitro histone H3 methyltransferase activity, demonstrated by an
assay in which Metnase catalyzed the transfer of radiolabeled 3H-methyl group
from the donor S-Adenosyl methionine (SAM) to histone H3. That experiment
showed that Metnase dimethylates histone H3 at lysine residue 36, and to a
much lesser extent Lysine 4 (but not lysines 9 or 79, which are correlated with
transcriptional repression) [139]. It is important to note that dimethylation of
lysines 4 and 36 in histone H3 is associated with open (active) chromatin [141145]. Thus, Metnase histone methylation activity may have important functions in
DNA repair, DNA replication, integration of foreign DNA into the genome, or
regulation of other aspects of DNA dynamics. Taken together, these
observations suggest that Metnase may be important for loosening DNA/histone
interactions and thereby increasing access of DNA repair factors to DNA in
chromatin through methylation of lysine 36 of histone H3. This hypothesis has
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been supported by a study of NHEJ (Appendix 6.4) and our results suggest that
it is the case.
Metnase also has automethylation activity that regulates its functional
interaction with TopoIIα in chromosomal decatenation [146]. Metnase was shown
to interact with TopoIIα and this interaction was important for chromosomal
decatenation during the M-phase of the cell cycle [146]. In vitro decatenation
activity of TopoIIα in the presence of purified Metnase protein was decreased
when the methyl donor SAM was added to the reaction. This study also showed
that the nuclease defective Metnase mutant D483A is less able to enhance the
decatenation activity of TopoIIα [146]. In the presence of TopoIIα inhibitors
ICRF-193 and VP-16, the decatenation checkpoint is activated, but this
checkpoint arrest could be bypassed by overexpression of Metnase [146]. The
enhanced decatenation activity with Metnase overexpression was also
demonstrated in leukemia and breast cancer cell lines [147, 148]. Thus, Metnase
has an important function in chromosomal decatenation, which is regulated by
automethylation and TopoIIα interactions, and Metnase may be an important
tumor marker as its expression likely influences cancer cell sensitivity to
topoisomerase inhibitors used in cancer chemotherapy.

2.6.5. Metnase roles in DNA repair
Metnase promotes NHEJ in vitro and in vivo, but not HR [139]. When
Metnase was overexpressed, end joining (precise and imprecise) was increased
by ~2 fold, and when the protein was knocked-down using siRNA there was a 12
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fold reduction in imprecise and 20 fold reduction in precise NHEJ [139].
Additionally, both SET and nuclease domains were shown to be important for
this stimulation of NHEJ, as N210S and D248S (SET defective), and D290S
(nuclease defective) mutations blocked Metnase NHEJ activity. Interestingly,
when Metnase siRNA knock-down cells were exposed to ionizing radiation,
whose damage is mainly repaired by NHEJ, there was an eight fold decrease in
colony survival. However, Metnase overexpression did not have a significant
effect in an HR assay [139]. Thus, Metnase was implicated as a DNA repair
protein involved specifically in the NHEJ repair pathway.
In 2008, the Lee laboratory characterized in a series of biochemical
experiments the interactions between Metnase and the protein hPso4, a human
homolog of the yeast protein PS04, that has been implicated in DNA repair and
cell survival through interactions with WRN [149]. Metnase was shown to
interact with NBS1, and to co-localize with this protein in IR induced nuclear foci.
Furthermore,

the

NBS1

interaction

by

co-immunoprecipitation

and co-

localization in foci was shown to be dependent on hPso4 [149]. Additionally, our
laboratory has previously demonstrated that Metnase interacts with the classical
NHEJ proteins Ligase IV (LigIV) and XRCC4, in a DNase independent manner,
thus Metnase has been shown to interacts with important components of the
NHEJ pathway [150].
The Hromas laboratory further characterized the role of Metnase in
promoting precise and imprecise NHEJ with different types of ends, namely 4
base 5’ overhangs, 4 base 3’ overhangs, and blunt ends, and in preventing
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deletions during NHEJ [150]. In addition, they demonstrated that although
Metnase does not have an effect in HR, it does promote resolution of γH2AX foci
after IR [150]. Taken together, these findings indicate that Metnase plays a
direct role in the NHEJ pathway. Our laboratory has recently conducted a
detailed mechanistic study of the role of Metnase in NHEJ. We showed that
Metnase promotes recruitment of early NHEJ factors to DSBs by dimethylating
histone H3 K36 (Appendix 6.4).
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2.7. Hypothesis
Studies have demonstrated that Metnase interacts with TopoIIα in vivo
and in vitro. This interaction is important for chromosomal decatenation during
the M-phase of the cell cycle, and cancer cells in which Metnase has been
repressed are sensitive to TopoIIα inhibitors. TopoIIα is also involved in DNA
replication and it has been isolated as part of the replisome complex [151].
Metnase methylates histone H3 at lysine 36 and this modification is associated
with transcriptional complexes [139, 141], which could be important during DNA
dynamic processes such as repair and DNA replication. Metnase plays a role in
NHEJ and although its specific functions are not fully elucidated, it appears to
regulate access of NHEJ factors to DSBs by dimethylating histone H3 Lysine 36
and it interacts with NHEJ proteins such as LigIV, XRCC4, and NBS1. DNA
replication fork damage is mostly repaired by the HR pathway; however, recent
studies have shown that NHEJ proteins such as DNA-PK and PARP-1 also play
a role in replication fork re-start. Therefore, since Metnase enhances TopoIIα
function and NHEJ repair, it is hypothesized that Metnase is involved in
replication fork re-start after damage.
The present study demonstrates that Metnase indeed is important for
replication fork re-start after damage as demonstrated by DNA fiber analysis and
BrdU incorporation assays. Cell cycle analysis demonstrated that cells lacking
Metnase have a delayed S-phase progression and increased sensitivity to
replication fork damaging agents. Furthermore, it is demonstrated that Metnase
interacts with replication fork factors, PCNA and the RAD9 subunit of the 9-1-1
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complex, and that it interacts with TopoIIα. The exact mechanism by which
Metnase acts in replication fork re-start is yet to be determined, but these
observations demonstrate that Metnase is important for the re-start of stalled
and replication forks, and its functions may be mediated by interactions with
replication fork components.
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3. METHODOLOGY
3.1. Materials and Methods
3.1.1. Cell Lines, RNAi-suppression of Metnase, and Expression of V5tagged Metnase
Cell lines were cultured in D-MEM with 10% (v/v) fetal bovine serum
supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin, or 1×
antimycotic/antibiotic (Invitrogen, Carlsbad, CA). Metnase was overexpressed in
HEK-293 and HEK-293T cells as described [146].

V5-tagged Metnase

expression was confirmed by Western blot with a monoclonal antibody against
the V5 tag (Invitrogen). Metnase was downregulated by transfecting cells with a
pRNA/U6-Metnase RNAi vector and selecting in growth medium with 150-200
µg/mL hygromycin B (Sigma-Aldrich, St. Louis, MO), or with a Metnase shRNA
vector (pRS-shMetnase), and selecting in growth medium with 1 µg/μL
puromycin. Control cells were transfected with empty pRNA/U6 or pRS-shGFP
vectors. Metnase expression was measured by RT-PCR and by Western blots
using antibodies to native Metnase as described [139].

3.1.2. Cell Proliferation and Replication Stress Sensitivity Assays
Cell proliferation was analyzed in triplicate in treated or mock-treated
populations incubated in fully supplemented media at 37°C, 5% CO 2 . At the
indicated times cells were harvested and counted with a Coulter counter. Cell
sensitivity to camptothecin (CPT) and hydroxyurea (HU) was determined by
seeding 1000 cells per 10 cm (diameter) dish in drug-free medium (to determine
plating efficiency, PE), and 100,000 cells per dish in medium with CPT or HU,
35

incubating for indicated times. Then cells were rinsed with PBS, fresh growth
medium was added, and cells were incubated for 12-14 days before colonies
were stained with 0.1% crystal violet in methanol and counted.

For UV-B

sensitivity assays, cells were seeded and incubated for 24 hours as above,
rinsed with PBS, exposed to UV-B in a biological safety cabinet equipped with a
Phillips UV-B fluorescent bulb, then fresh growth medium was added and cells
were incubated and colonies scored. UV doses were determined by using a
UVX dosimeter (UVP, Upland, CA).

PE was calculated as the number of

colonies divided by the number of cells plated without drug or UVB treatment.
Percent survival was calculated as the number of colonies formed with drug or
UV-B treatment divided by the number of cells plated times the PE.

3.1.3. Analysis of Cell Cycle Distributions and Cell Death
Cell cycle distributions were measured by fixing cells with 70% ethanol
and staining with 0.2 mg/mL propidium iodide (PI) in a fresh solution containing
1% (v/v) Triton X-100 and 2 U of DNAse-free RNAse (all from Sigma-Aldrich) for
15 min at 37°C or at 30 min at room temperature. Samples were analyzed using
a FACScan or a FACScalibur flow cytometer (Becton Dickinson, Franklin Lakes,
NJ). The percentages of cells in G 1 , S, or G 2 /M phases were calculated by
dividing the number of cells in each cell cycle stage by the total number of PI
positive cells, normalizing to controls that were not stained with PI, and
converting values to percentages). Apoptosis and cell death were analyzed by
flow-cytometric measurement of annexin-V expression and PI incorporation by
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using the Annexin V-FITC Apoptosis Detection Kit I (BD Pharmingen, San Diego,
CA). All flow cytometry data were analyzed with FlowJo software (Ashland, OR,
http://www.flowjo.com/).

3.1.4. BrdU Incorporation
Log phase cells, or cells treated with 5 mM HU for 18 h were washed with
PBS and released into fully supplemented D-MEM containing 10 μM BrdU.
Aliquots were removed at indicated times, cells were fixed, permeabilized, and
stained using the FITC BrdU Flow Kit (BD Pharmingen), and analyzed by flow
cytometry as above.

3.1.5. DNA Fiber Analysis
DNA fibers were analyzed as described [99]. Briefly, cells were grown to
~50% confluence in six-well tissue culture dishes, 20 μM IdU was added to
growth medium (fully supplemented), mixed and incubated for 10 min at 37°C.
Media was removed and cells were washed with PBS, followed by a 100 μM
thymidine wash. Cells were then either treated with HU, KU55933 (an ATM
inhibitor; KuDOS, Cambridge, England), VP16 (etoposide, a TopoIIα inhibitor),
ICRF-193 (TopoII inhibitor), NU1025 (a PARP-1 inhibitor; KuDOS, Cambridge,
England), or mock treated. The culture medium was then replaced with fresh
medium containing 20 μM CldU and cells were incubated for 20 min at 37°C.
Cells were harvested, resuspended in PBS, 2500 cells (2 μL) were transferred to
a positively charged microscope slide (Superfrost/Plus, Daigger, Vernon Hills,
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IL), lysed with 6 μL of 0.5% SDS, 200 mM Tris-HCl, pH 7.4, 50 mM EDTA, and
incubated at room temperature for 5-10 min (a longer incubation may be
required at lower altitudes or more humid climates). Slides were tilted to allow
DNA to spread via gravity, covered with aluminum foil, air-dried for 8 min, fixed
for 5 min with 3:1 methanol:acetic acid (prepared fresh), air dried for 8 min, and
stored in 70% ethanol at 4°C overnight. Slides were deproteinized in 2.5 N HCl
at 37°C for 1 hr, blocked with 5% BSA and labeled sequentially for 1 hr each
with mouse anti-BrdU antibody (BD Biosciences, San Jose, CA), secondary goat
anti-mouse Alexa-568 (Invitrogen), rat anti-BrdU (Accurate Chemical, Westbury,
NY), and secondary donkey anti-rat Alexa-488 (Invitrogen); all antibodies were
used at 1:100 dilution and incubated for 1 h at 37°C. Slides were mounted in
PermaFluor

aqueous,

Waltham, MA).

self-sealing

mounting

medium

(Thermoscientific,

DNA fibers were visualized using an LSM 510 confocal

microscope (Zeiss, Thornwood, NY) optimized for each Alexa dye. Images were
processed with Zeiss LSM Image Browser software. In some cases, images
were further processed with Photoshop (Adobe) and Genuine Fractals (onOne)
software. All images in each experiment were identically processed.

3.1.6. Analysis of γ-H2AX Positive Cells
Cells grown to ~50% confluence in six-well tissue culture dishes were
treated with 10 mM HU for 18 h in fully supplemented D-MEM, released into fully
supplemented D-MEM for indicated times, harvested, cytospun, and fixed with
paraformaldehide as described previously [148]. Cells were re-hydrated in PBS
38

for 5 min at room temperature and blocked with 2% BSA in PBS for 30 min.
Primary staining was done with γ-H2AX monoclonal mouse antibody (Merck,
Nottingham, UK) and overnight incubation at 4°C. Cells were washed 3 times in
TBS-T for 5 min at room temperature and secondary staining was accomplished
with an Alexa488-tagged goat anti-mouse antibody (1:500 dilution, Invitrogen)
for 1 h at room temperature. The cells were washed 3 times in Tris-buffered
saline-tween (TBS-T) for 5 min at room temperature, then covered in Vectashield
mounting media containing 4',6-diamidino-2-phenylindole (DAPI [1.5 μg/mL])
(Vector Laboratories, Burlingame, CA) and sealed with clear nail polish. Images
were obtained with a Radiance 2100 inverted confocal microscope (BioRad,
Hercules, CA) fitted with filter sets specific for DAPI and FITC/Alexa488. Images
were optimized consistently with ImageJ software (http://rsb.info.nih.gov/ij/).

3.1.7. Protein Immunoprecipitation
Whole cell extracts were obtained using mammalian-protein extraction
reagent (M-PER) buffer according to the manufacturer’s instructions (Thermo
Scientific), and protein concentration was quantified using a standard Bradford
assay. Protein samples were pre-treated with 4 U of DNaseI, incubated at 37°C
for 10 min, immunoprecipitated using 0.5-5 mg of protein and antibodies to V5
(1:500, Invitrogen), PCNA (1:1000, Abcam, Cambridge, MA), Rad9 (1:1000,
Abcam), or TopoIIα (1:500, TopoGEN, Port Orange, FL). Samples were
incubated overnight at 4°C, then 25 μL of A/G (1:1) agarose beads (Invitrogen)
were added, samples were incubated for 2 h at 4°C, and centrifuged at 300 × g
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for 2 min at 4°C. Supernatants were removed and beads were washed four
times

with

M-PER

buffer

(Thermoscientific)

containing

50

mM

phenylmethanesulphonylfluoride and 1x protease and phosphatase inhibitor
mixture (Invitrogen). Beads were centrifuged at 300 × g for 2 min at 4°C, boiled
for 10 min, and centrifuged at 300 × g for 2 min at 4°C. The supernatants were
transferred to new tubes; samples were boiled for 10 min, separated by SDSPAGE, transferred to a PVDF membrane, and analyzed by Western blotting.

3.1.8. Relaxation of Positive Supercoiled DNA
Positively supercoiled DNA was a kind gift from Dr. Neil Osheroff and Amanda
Gentry (Vanderbilt University) prepared as described [120]. Positive supercoil
relaxation reactions were performed in a total volume of 20 μL in 10 mM TrisHCl, pH 7.9, 175 mM KCl, 0.1 mM EDTA, 5 mM MgCl 2 , 2.5% glycerol, 0.5 mM
ATP (USB Co., Cleveland, OH), 2 U TopoIIα, 180 ng Metnase (when noted), and
0.3 μg DNA. Aliquots were removed at indicated times and reactions were
stopped with 4 μL of 0.77% SDS, 77 mM EDTA. Products were separated on
1% agarose gels and densitometry was performed using Image J software.
Background values were subtracted from signals. The resulting values were
normalized to signals at initial time points, and plotted as function of time in two
independent experiments.
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4. RESULTS
4.1. Metnase Promotes Cell Proliferation
Metnase is expressed in a wide variety of human tissues [139] and in all
human cell lines tested, except those transformed by T-antigen such as HEK293T cells (unpublished results).

Overexpression of Metnase in HEK-293T

increases cell proliferation [146]. HEK-293 cells express Metnase, and stable
shRNA knockdown of Metnase in HEK-293 cells significantly reduced the cell
proliferation rate compared to control cells (Fig. 4-1A). We confirmed in this
study that Metnase overexpression in HEK-293T increases cell proliferation (Fig.
4-1B). Moreover, cells stably transfected with Metnase shRNA vectors either
cease to proliferate after 2-3 months, or revert to a normal phenotype, and
escape Metnase repression.

These results indicate that Metnase promotes

proliferation of human cells, and suggest that Metnase is very important for
growth of human cells that do not express T antigen.

41

Figure 4-1. Metnase promotes cell proliferation.
A) Cell growth was monitored in HEK-293 cells transfected with shGFP
(control) or shMetnase vectors. B) Cell growth was monitored in HEK-293-T
cells, which do not normally express Metnase, transfected with the pCAPPMetnase expression vector or empty pCAPP. Plotted are averages (±SD) of 2-3
determinations per time-point. * indicates P<0.05, ** indicates P<0.01. Metnase
expression is shown in representative Western blots with β-actin loading control
(insets).
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4.2.

Metnase Promotes Cell Survival and DNA Replication After
Replication Stress
The effect of Metnase on cell proliferation, coupled with its DNA repair

properties and functional interaction with TopoIIα [139, 146], suggested that
Metnase may have a role in replication and/or in rescuing cells from replication
stress at sites of spontaneous or induced DNA damage. We therefore tested
whether Metnase regulates sensitivity to replication stress induced by
hydroxyurea (HU), camptothecin (CPT), and UV-B (Fig. 4-2). Metnase
knockdown sensitized HT1080 cells to 1 mM HU by more than 1000-fold (p =
0.01), and to 0.2-0.5 µM CPT by nearly 10-fold (p ≤ 0.011) (all statistical
analyses in this study were performed by using t tests). Metnase knockdown
sensitized HEK-293 cells to a UV-B dose of 11.2 J/m2 by nearly 20-fold (p =
0.007). When cultured in a low concentration of HU (0.1 mM), HEK-293 cells
proliferated at a slow rate, but Metnase knockdown cells showed almost no
proliferative capacity; this effect specifically reflects the Metnase defect since
Metnase overexpression in HEK-293T significantly enhanced proliferation under
these conditions (Fig.4-3A). The hypersensitivity of Metnase knockdown cells to
replication stress reflects, at least in part, enhanced cell death via apoptosis
(Fig. 4-3B), as shown by the nearly 30-fold increase in the apoptosis marker
annexin V, and >6-fold increase in inviable cells (unable to exclude propidium
iodide) (both p < 0.005). The marked sensitivity of Metnase knockdown cells to
replication stress contrasts with their mild sensitivity to ionizing radiation [139],
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perhaps because the replication stressors HU, CPT, and UV-B were
continuously present.
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Figure 4-2. Metnase promotes colony survival after DNA replication stress.
Average percent cell survival (± SD) after HU, CPT, or UV-B treatments
measured as relative plating efficiency

for HT1080 or HEK-293 cells stably

transfected with control or shRNA-Metnase vectors.

Data are from 2-3

independent experiments per condition; * indicates p < 0.05, ** indicates p <
0.01. Values are averages (±SD) from 3 independent experiments.

44

B

A

Figure 4-3. Metnase promotes cell growth and prevents apoptosis after
DNA replication stress.
A)

Average growth rates (±SD) of control HEK-293 and sh-Metnase

knockdown cells, and control HEK-293T or Metnase overexpression cells in
medium containing 0.1 mM HU; data are from 2-3 independent experiments per
cell line. B) HEK-293 control or Metnase knockdown cells were treated with 5
mM HU for 6 h and the percentages of cells expressing annexin V or
incorporating propidium iodide were determined by flow cytometry. Data are
from 2-3 independent experiments per condition; * indicates p < 0.05, **
indicates p < 0.01.
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To investigate the mechanism by which Metnase promotes cell
proliferation and resistance to replication stress, we tested whether Metnase
expression level influenced DNA replication by measuring BrdU incorporation
and cell cycle distributions by flow cytometry, in unstressed cells and after
release from replication stress.

In log phase (untreated) HEK-293 cells,

Metnase knockdown had no effect on BrdU incorporation during a 30 min
incubation (Fig. 4-4A).

However, when cells were pretreated with 5 mM HU for

18 h and then released into BrdU, Metnase knockdown in HEK-293 significantly
reduced BrdU incorporation (~2-fold), and Metnase overexpression in HEK-293T
significantly increased BrdU incorporation (Fig. 4-4B, C). Although neither overnor underexpression of Metnase significantly affected cell cycle distributions of
unstressed cells (Fig. 4-5A), when treated with 5 mM HU for 18 h and released,
HEK-293T cells overexpressing Metnase entered S-phase more rapidly than
control cells (seen 1 h after release from HU), and entered G2 phase more
rapidly (seen 7 h after release from HU (Fig. 4-5B). Somewhat stronger effects
were seen when Metnase was overexpressed in HEK-293 cells (Fig. 4-6); this
may reflect the fact that HEK-293T cells show robust proliferation even though
they do not express Metnase. When HEK-293 Metnase knockdown cells were
treated with 5 mM HU for 18 h and released, the opposite effect was seen. In
two independent knockdown cell lines, there were marked accumulations of S
phase cells 10 and 18 h after release from HU (Fig. 4-7), indicating that Metnase
knockdown prolongs S phase after replication stress.
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Figure 4-4.

Metnase promotes DNA replication after release from

replication stress.
A) Log phase HEK-293 cells expressing normal or low levels of Metnase
were incubated with 10 µM BrdU for 30 min and average percentages (±SD) of
BrdU+ cells are shown for two determinations per strain. B) HEK-293 control and
Metnase knockdown cells were treated with 5 mM HU for 3 h and released into
medium with 10 µM BrdU. Average fold increases (±SD) in the percentage of
BrdU+ cells relative to untreated cells (no HU, no BrdU) are plotted for 3
independent experiments per cell line. C) BrdU incorporation after HU release in
HEK-293T control and Metnase overexpression cells as in panel B, except cells
were treated with HU for 18 h. For all three panels * indicates p < 0.05, **
indicates p < 0.01.
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Figure 4-5. Metnase over expression promotes cell cycle progression after
replication stress in HEK 293T cells.
A) Cell cycle distributions of log phase cultures of HEK-293T cells stably
transfected with empty or Metnase overexpression vectors. B) Cell cycle
distributions of HEK-293T cells, with or without Metnase overexpression, after 18
h treatment with 5 mM HU and release into normal growth medium for indicated
times. Values are averages (±SD) of three experiments; * indicates p < 0.05, **
indicates p < 0.01.
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A

B

Figure 4-6. Metnase overexpression promotes cell cycle progression after
replication stress in HEK293 cells.
A) Cell cycle distributions of log phase cultures of HEK-293 cells stably
transfected with empty or Metnase overexpression vectors. Values are from one
experiment. B) Cell cycle distributions of HEK-293 cells, with or without Metnase
overexpression, after 18 h treatment with 5 mM HU and release into normal
growth medium for indicated times.

Values are averages (±SD) of three

independent experiments; * indicates p < 0.05, ** indicates p < 0.01.
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A

B

Figure 4-7.

Metnase promotes cell cycle progression after replication

stress in HEK293 cells.
A) Cell cycle distributions of log phase cultures of HEK-293 cells stably
transfected with shRNA control or shRNA Metnase vectors. Values are from one
experiment. B) Cell cycle distributions of HEK-293 cells transfected with shRNA
control or shRNA Metnase vectors, after 18 h treatment with 5 mM HU and
release into normal growth medium for indicated times. Values are averages
(±SD) of three experiments; * indicates p < 0.05, ** indicates p < 0.01.
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4.3.

Metnase Promotes Replication Fork Restart
To gain a better understanding of the role of Metnase in replication and

the replication stress response, we analyzed replication fork restart, new origin
firing, and replication speed by using DNA fiber analysis. Log phase HEK-293
cells stably transfected with vectors expressing shRNA targeting Metnase, or
GFP as control, were labeled with IdU for 10 min, then incubated with or without
5 mM HU for one h, briefly washed with thymidine and then incubated with CldU
for 20 min. Cells were lysed on glass slides and DNA fibers were stretched by
gravity, fixed, IdU was stained red and CldU was stained green, and DNA fibers
were quantified using confocal-microscopy (Figures. 4-8 and 4-9A). In untreated
control cells, ~90% of fibers showed adjacent red-green signals indicative of
continuing forks, and ~10% had only green signals indicating forks that initiated
after IdU was removed (“new forks”). When control cells were treated with HU,
continuing forks (those that stalled and restarted) were moderately reduced to
~65% (p = 0.0014), new forks that initiated after HU treatment showed a slight
but not statistically significant increase to ~20%, and ~15% of forks stopped and
failed to restart. The pattern observed with untreated Metnase knockdown cells
was similar to untreated wild-type cells, with predominantly continuing forks and
a small percentage of new forks. Strikingly, when Metnase knockdown cells
were treated with HU, the percentage of stopped forks greatly increased (to
~90%) and there was a corresponding large decrease in the percentage of
continuing forks (both P ≤ 0.0008). New forks were extremely rare in HU treated
Metnase knockdown cells, however new forks are also rare in untreated
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Metnase knocked-down cells, and the decrease with HU treatment was not
statistically significant (p = 0.3).

These results provide direct evidence that

Metnase plays a critical role in restarting stalled replication forks, and further
suggest that Metnase may regulate new origin firing when cells experience
replication stress.
To determine whether Metnase regulates the speed of replication, we
measured average fiber lengths.

As expected, red fibers were shorter than

green since cells were treated with IdU (red) for 10 min and CldU (green) for 20
min. Fibers were longer in unstressed cells than after HU treatment (Figure 49B). However, Metnase had no effect on fiber lengths in either HU treated or
untreated cultures.

We conclude that Metnase regulates the efficiency of

replication fork restart, and possibly initiation after replication stress, but it has
no effect on the speed of ongoing forks.
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Figure 4-8. Metnase promotes replication fork restart.
HEK-293 cells transfected with sh-GFP control or shMetnase were treated
with HU. IdU and CldU labeling scheme is shown above representative confocal
microscope images of DNA fibers, with IdU stained red and CldU stained green.
Images were obtained using an LSM 510 confocal microscope and are
representative of four independent experiments, each done in triplicate.
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A

B

Figure 4-9. Metnase promotes replication fork restart.

A) Quantification of fiber images in Figure 3.8. At least 150 fibers were
scored per treatment, per cell line in each of three experiments; ** indicates p <
0.01.

B) Fiber lengths were measured by using LSM 510 Image Browser

software. Plotted are averages (±SD) of triplicate experiments in which 150-500
fibers were scored per treatment, per experiment, nd=none detected.
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4.4.

Metnase Promotes Resolution of γ-H2AX Induced by Replication
Stress
Replication

stress

causes

fork

collapse

to

DSEs

marked

by

phosphorylation of histone H2AX to γ-H2AX. Elimination of the γ-H2AX signal
over time reflects DSE/fork repair.

Metnase and classical NHEJ proteins

promote survival after replication stress and influence replication fork restart
[99, 164-166] (this study), and Metnase promotes NHEJ and interacts with the
key NHEJ protein DNA LigIV [139, 150]. We therefore tested whether Metnase
influences resolution of HU-induced γ-H2AX by treating cells with 10 mM HU for
18 h, then releasing into normal growth medium and examining γ-H2AX by
immunofluorescence microscopy. Since HEK-293 and HEK-293T cells used in
these experiments adhere poorly, cells were cytospun prior to fixation and
immunocytochemical staining. Consistent with the enhanced sensitivity of
Metnase knock-down cells to HU, γ-H2AX persisted longer in the knock-down
cells, with significant differences from controls at both 6 and 24 h after release
from HU (Figure 4-10A, p < 0.0001). Similarly, overexpression of Metnase in
HEK-293T cells accelerated the resolution of γ-H2AX signals (Figure 4-10B (p ≤
0.0055). Note that in all four cell lines, similar percentages of cells were γ-H2AX
positive at the end of the 18 h HU treatment.

These results indicate that

Metnase promotes resolution of γ-H2AX after cells are released from replication
stress, but Metnase does not prevent fork collapse to DSEs over the course of
this relatively long HU treatment.
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Figure 4-10. Metnase promotes resolution of replication stress-induced γH2AX.
(A) HEK-293 and HEK-293T cells over- or under-expressing Metnase
were treated with 10 mM HU for 18 h and released into growth medium for 24 h.
Aliquots of cells were removed at indicated times, cytospun, stained with DAPI
(blue) and antibodies to γH2AX and imaged by confocal microscopy. (B)
Percentage of γ-H2AX positive cells among total DAPI stained cells were. An
average of >190 cells were counted per slide, 10 slides in each of three
independent experiments. Values are plotted as average (±SD); ** indicates p <
0.01.
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4.5. Metnase Co-immunoprecipitates with PCNA and RAD9
Since Metnase is involved in the replication stress response, we explored
its interactions with proteins at the replication fork.

PCNA is a key scaffold

protein that mediates binding of numerous proteins in the replisome and
promotes replication processivity . Metnase co-immunoprecipitated with PCNA,
and vice versa, in unstressed cells and after treatment with HU (Figure 4-11A).
PCNA interacts with many proteins that share a conserved binding motif, the PIP
box, and Metnase has a PIP box (aa 121-128) with the same conserved amino
acids found in PIP boxes in three PCNA interacting proteins, DMNT, DNA
polymerase β, and RecQL5 . Interestingly, Metnase also co-immunoprecipitated
with RAD9, a member of the 9-1-1 complex that is structurally and functionally
related to PCNA, and that is recruited to stalled and/or collapsed replication
forks (Figure 4-11B). Although this interaction appeared stronger when RAD9
was immunoprecipitated from HU treated cells, a similar enhancement was not
seen with HU treatment when Metnase was immunoprecipitated. Metnase did
not co-immunoprecipitate with the 32 kDa subunit of RPA (Figure 4-11C),
indicating that Metnase is present within the replisome, but is not closely
associated with ssDNA at stalled forks. These results indicate that Metnase is
closely associated with replication stress factors that control TLS, fork
processing via HR mechanisms, and checkpoint signaling.
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Figure 4-11. Metnase interacts with PCNA and RAD9, but not RPA32.
A) Reciprocal co-immunoprecipitation of V5-tagged Metnase and native
PCNA from cells treated with 5 mM HU for 18 h, tested immediately or 30 min
after

release

from

HU,

or

untreated.

Input

represents

0.5%

of

immunoprecipitation. Results are representative of at least three independent
experiments. B, C) Reciprocal co-immunoprecipitation of V5-tagged Metnase
with native RAD9 and native RPA as in panel A, except HU treated cells were
only tested immediately after treatment.
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4.6. Metnase Interacts with TopoIIα and Promotes TopoIIα-Dependent
Relaxation of Positively Supercoiled Plasmid DNA
Metnase interacts with TopoIIα and promotes TopoIIα-dependent
chromosome decatenation [146]. TopoIIα is present in the replisome [122] and
may function in DNA replication by relaxing of positive supercoils that
accumulate ahead of replication forks [120].

We found that Metnase

significantly enhanced TopoIIα-dependent relaxation of positive supercoils
during a 5 min time course, but Metnase was not required to achieve full
relaxation within an hour (Figure 4-12A, B).

To gain insight into whether

Metnase functions in the replication stress response through its interaction with
TopoIIα, we tested whether the interaction between Metnase and TopoIIα was
affected by replication stress. HEK-293 cells were treated with 5 mM HU for 3 h,
and cell extracts were prepared and analyzed by co-immunoprecipitation of
Metnase and TopoIIα. As shown in Figure 4-12C, Metnase and TopoIIα show a
robust interaction regardless of which protein was immunoprecipitated, but this
interaction was not affected by HU treatment.

These results suggest that

Metnase interaction with TopoIIα may promote TopoIIα processing of DNA
structures in front of replication forks.
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Figure 4-12. Metnase interacts with TopoIIα and stimulates relaxation of
positive supercoils.
A) Predominantly positively-supercoiled plasmid DNA samples were
treated with TopoIIα (2 U) with or without Metnase (180 ng) for indicated times,
and topological forms were detected on ethidium bromide stained agarose gels.
B) Gel images were scanned and the percentage of positively-supercoiled DNA
remaining at each time point was quantitated. Values are averages (±SD) of two
determinations per condition, normalized to 100% at t=0; ** indicates p < 0.01.
C) Co-immunoprecipitation of V5-tagged Metnase and native TopoIIα; data
presented as in Fig. 7B.
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4.7. TopoIIα is not required for replication fork progression after DNA
replication damage in cells expressing normal levels of Metnase
Based on our observations that Metnase interacts with TopoIIα and
stimulates the relaxation of positive supercoils, we decided to investigate
whether TopoIIα, perhaps through its interaction with Metnase, regulates
replication fork re-start. We performed a DNA fiber assay using the TopoIIα
inhibitor, ICRF-193, at two different concentrations [10 μM] and [25 μM] , and
added it to cells treated with 5 mM HU for 1 h (Figure 4-14). The DNA fibers
were quantified as described earlier (Methods section). The results shown in
Figure 4-13A and B shown no significant difference in the fractions of new,
stopped, or continuing forks, in normal HEK-293 cells or in Metnase knock-down
cells upon treatment with ICRF-193. This suggests that the TopoIIα inhibition by
ICRF-193 does not have an effect on replication fork re-start; therefore, TopoIIα
does not appear to be directly involved in this process. We further investigated
whether a second TopoIIα inhibitor, VP16 (which has been shown to affect cell
growth in cancer cells lacking Metnase [147]), or a combination of VP16 and
ICRF-193 would prevent timely replication fork restart in HEK-293 cells
expressing normal levels of Metnase. The results shown in figure 4-14ABC
indicate that there is no significant difference between treated cells and controls,
as seen with ICRF-193 alone (Figure 4-13). It is important to note that the levels
of stopped, new, and continuing forks are similar to the ones observed in the
normal untreated controls (Figure 4-9A). Taken together these results indicate
that TopoIIα is not directly involved in restarting stalled replication forks, and
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therefore, the strong effect of Metnase on replication fork restart is likely to be
independent of its interaction with TopoIIα.
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Figure 4-13.

Topoisomerase II inhibitor ICRF-193 does not affect

replication fork restart.
HEK-293 cells expressing normal levels of Metnase or shRNA Metnase
were exposed to TopoII inhibitor A) ICRF-193 [1 μM] and subsequently labeled
with IdU, treated with HU [5 mM] for 1 h, and labeled with CldU. B) Cells were
treated with ICRF-193 [25 μM] only, in the absence of HU treatment. The
quantification of stopped forks, new forks, and continuing forks, plotted are
averages (±SD) of triplicate experiments in which 150-500 fibers were scored
per treatment, per experiment. Values are averages (±SD) of three experiments;
** indicates p < 0.01.
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Figure 4-14. Topoisomerase II inhibitors ICRF-193 and VP16 do not affect
replication fork restart after replication fork stress.
HEK 293 cells expressing normal levels of Metnase were exposed to
TopoII inhibitors VP16 [25μM] and ICRF-193 [25μM] in the presence of HU [5
mM] for one hour. Quantification of stopped forks (red), new forks (green), and
continuing forks (yellow) are plotted as averages (±SD) of triplicate experiments
in which 150-500 fibers were scored per treatment, per experiment.
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4.8. ATM plays a role in replication fork re-start independently of Metnase
ATR and ATM are signaling kinases involved in detection of different
types DNA damage, including replication damage. By phosphorylating histones
and other proteins, these kinases also promote recruitment of DNA repair
proteins to DSBs. We investigated whether ATM functions with Metnase in
replication fork restart by inhibiting ATM in normal and Metnase knock-down
cells and assaying replication with the DNA fiber assay.
We addressed two questions: 1) Does ATM inhibition affect fork restart in
wild type cells, and 2) is there genetic interactions between Metnase and ATM in
fork restart (Metnase knocked-down). HEK-293 cells were treated with the ATM
inhibitor KU55933 [10 μM], for 1 h under normal DNA replication conditions (log
phase growing cells), and analyzed the DNA fibers as described earlier
(Methods section). The control cells showed a significant increase in stopped
forks (6.4 fold) in the presence of ATM inhibitor, p< 0.01 (Figure 4-15), reflecting
a decrease (from 90.3% to 69.1%, p< 0.01) in continuing forks.

These

observations confirm that ATM plays an important role in replication fork repair.
In Metnase knock-down cells, we also observed a significant increase in stopped
forks (6 fold), p< 0.05, and a decrease in continuing forks (from 92.9% to 63.4%,
p< 0.01). However, there were no differences in the percentages of stopped,
new, and continuing forks between cells with normal and reduced Metnase in the
presence of the ATM inhibitor, this suggests that Metnase may operate upstream
of ATM or vice versa.
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Figure 4-15. ATM is important for normal replication fork re-start, but
functions independently of Metnase.
HEK293 cells containing normal or reduced levels of Metnase were
treated with KU55933 [10 μM], an ATM inhibitor, for 1 hr under normal DNA
replication conditions (i.e. log growing cells). At least 150 fibers were scored per
treatment, per cell line for each of three experiments; * p≤ 0.05, ** p ≤ 0.01.
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To further investigate the relationship between ATM and Metnase, we
performed a colony survival assay using HEK-293 cells stably expressing
shRNA control or shMetnase vectors, and KU55933 [70] at increasing doses for
the entire period of the assay (~12 days). The results (Figure 4-16) showed no
difference in colony formation ability of Metnase knock-down cells compared to
controls. ATM inhibition kills in the presence or absence of Metnase, suggesting
that Metnase and ATM function in the same pathway.
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Figure 4-16. Metnase and ATM function in the same pathway.
Average percent cell survival (± SD) after KU55933, an ATM inhibitor.
Treatments measured as relative plating efficiency for HEK-293 cells stably
transfected with control or shRNA-Metnase vectors.
experiments per condition, values are averages (±SD).
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Data are from 3

4.9. Metnase Regulates Chk1 Phosphorylation During Replication Stress
Chk1 is a protein kinase that acts downstream of ATM/ATR kinase and is
important in the DNA damage checkpoint control [167]. Chk1 becomes activated
via phosphorylation of Ser 317 and Ser 345, which occurs in response to
blocked DNA replication [168]. Ser 345 phosphorylation localizes Chk1 to the
nucleus following checkpoint activation [169]. However, it has been shown
recently that phosphorylation at Ser 317, in conjunction with phosphorylation of
PTEN, is important for reentry into the cell cycle after replication fork stalling
[170]. We examined Chk1 phosphorylation status of serine 317 in the presence
and absence of Metnase after HU. We predicted that if Metnase operates
upstream of Chk1, then when we inhibit Metnase we would see a change in
Chk1 phosphorylation status after replication fork stalling. HEK-293 cells
expressing normal or reduced levels of Metnase were treated with 5 mM HU for
three hours and the phosphorylation status of Chk1 was then analyzed via
Western blot. Figure 4-17A is a representative autoradiograph of two
experiments showing Chk1 p-Ser 317, total Chk1, and actin as a loading control.
The bands on both gels were quantified using ImageJ (Figure 4-17B) and
protein amounts were normalized to untreated controls. The results show that
cells lacking Metnase fail to activate Chk1 (p-Ser 317) in response to HU and
they fail to increase total levels of Chk1. These observations suggest that
Metnase may be a regulator of Chk1 function in response to replication fork
damage.
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Figure 4-17. Metnase affects Chk1 phosphorylation after DNA replication
stress.
A) HEK-293 cells under-expressing Metnase or expressing normal levels
of Metnase were treated with 5 mM HU for 3 h, cells were subsequently lysed
and protein extracted to check for Chk1 phosphorylation status using an
antibody against Chk1 Serine 317 (which allows re-entry into the cell cycle after
stalled DNA replication). Results are representative of two independent
experiments. B) Quantification of A, done using ImageJ software. Chk1 and
Chk1-P bands were normalized to actin controls, and compared to untreated
controls that were assigned a value of 1 (dotted line).
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4.10. Metnase Promotes Resolution of PARP-1 Foci After Replication Fork
Damage
Recently proteins involved in NHEJ, such as PARP-1 and DNA-PK, have
been implicated in the repair of stalled replication forks. Specifically, PARP-1
has been shown to be activated at stalled replication forks in an Mre11dependent fashion (a member of the MRN complex) [132]. Furthermore, the Lee
laboratory has shown that Metnase interacts with Nbs1, another member of the
MRN complex [149]. Thus, we investigated whether PARP-1 and Metnase
function in the same or different replication fork restart pathways. We used
HEK293 cells expressing normal or reduced levels of Metnase for this analysis.
Cells were treated simultaneously with 5 mM HU and NU1025 [10 μM] (a PARP1 inhibitor) for 5 h. Subsequently cells were fixed, permeabilized, and stained to
visualize PARP-1 foci. Figure 4-18A shows the quantification of the PARP-1 foci
plotted as average foci per cell. The results show that cells lacking Metnase
have significantly (p < 0.01) more foci per cell after damage by HU than control
cells. Additionally, figure 4-18B shows a greater percentage of Metnase knockdown cells had more than five foci per cell compared to control cells. These
results suggest that Metnase functions to resolve PARP-1 foci formed because
of DNA replication fork damage; thus, possibly regulating the type of repair used
at the fork. Alternatively, lack of Metnase could increase DSBs at stalled forks,
which could lead to more PARP-1 foci independent of Metnase.
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B

Figure 4-18.

Metnase promotes resolution of replication stress-induced

PARP-1 foci.
A) HEK-293 cells under-expressing Metnase were treated with 5 mM HU
and KU55933 [10 μM] simultaneously for 5 h, cells were removed at indicated
time, fixed, and permeabilized with paraformaldehyde, stained with DAPI (blue)
and antibody to PARP-1 and imaged by confocal microscopy. On the
supplement (next page) are representative microscopy images of cells stained
with DAPI (blue), and PARP-1 (green). Average number of PARP-1 foci per cell
were quantified and plotted, and percentage of all cell counted containing more
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than 5 PARP-1 foci per cell was plotted as percentage.

An average of >190

cells were counted per slide, 3 slides per treatment for three independent
experiments. Values are plotted as average (±SD); ** indicates P ≤ 0.01.
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5. DISCUSSION
5.1. Metnase promotes cell proliferation
Early observations indicated that Metnase knock-down cells were mildly
sensitive to ionizing radiation [139]. We also noticed that these cells grew slower
than their normal Metnase expressing counterparts (Figure 4-1). This led us to
hypothesize that the slow growth phenotype of the knock-down cells may be due
to a replication defect. Therefore, we tested whether these cells would be
susceptible to other DNA damaging agents. In colony formation assays, we
discovered that Metnase knock-down cells were very sensitive to UV radiation
(20 fold), HU (1000 fold), and CPT (10 fold) (Figure 4-2), all of which cause DNA
replication fork stress (although UV also causes other types of stress, such as
thymidine dimmers). These observations supported our hypothesis that Metnase
may somehow play an important role in DNA replication fork stress and led us to
investigate the role of Metnase in DNA replication in more detail.

5.2. Metnase promotes restart of stalled and collapsed replication forks
Metnase appeared very late in evolution, in anthropoid primates [134].
Yet, it is an important protein that influences several aspects of DNA metabolism
including NHEJ, DNA integration, and chromosome decatenation [139, 146, 149,
150].

Through interaction with TopoIIα, it regulates cellular resistance to

common chemotherapeutics [147, 148].

This research establishes another

important role for Metnase in the replication stress response and provides
possible mechanisms of action. Given its late appearance in evolution, it is not
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surprising that Metnase does not influence normal replication fork progression.
Instead, Metnase functions during replication stress. Replication fork damage
and restart have historically been defined by using four assays: BrdU
incorporation assay, propidium iodide (PI) staining for flow cytometric cell cycle
analysis, replication fork bubble arc analysis, and more recently, DNA fiber
analysis. In this work, we have used three of the four methodologies to define
Metnase’s role in the DNA replication stress response.
The role of Metnase in replication fork repair became clearer after we
analyzed cells overexpressing and underexpressing this protein. Metnase levels
affected BrdU incorporation, S phase progression by PI staining, and fork restart
by DNA fiber analysis, but only when cells were subjected to replication stress
(Figures 4-4 - 4-9). Metnase knockdown conferred a marked defect in BrdU
incorporation after 3 h HU treatment compared to the control cells, and the
opposite observation was made when cells overexpressed Metnase (Figure 4-4).
Yet, under normal growth conditions, cells lacking Metnase incorporated BrdU at
the same rate as the control cells. Since HU acts by causing nucleotide pools to
be depleted, it can be concluded that Metnase plays a role in replication fork
progression after stress, but not under normal replication conditions. The slower
proliferation in Metnase knocked-down cells can be explained by sources of
intrinsic replication fork stress causing the forks to stall. This suggests that
Metnase’s function is not essential for normal DNA replication, but rather is
important to resolve stalled/collapsed replication forks.
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Cell cycle analysis of cells lacking or overexpressing Metnase supported
the hypothesis that it plays a role in replication fork stress recovery, but not in
normal DNA replication. We used HEK-293T cells, which the Hromas laboratory
discovered do not express Metnase (Figure 4-1), to analyze the effects of
Metnase status in cell cycle progression. Metnase levels did not affect cell cycle
progression in actively growing cells, with the exception of a slight increase in
the number of cells in S-phase in HEK-293T overexpressing Metnase (Figure 45A). However, these cells had a delayed progression through S-phase when
treated with HU and released, compared to cells overexpressing Metnase
(Figure 4-5B). This delay was overcome by 24 h post treatment with HU. Thus,
the S phase defect was not permanent and the cells were able to overcome the
lack of Metnase. We observed similar results in HEK-293 cells overexpressing
and under expressing Metnase (Figures 4-6 and 4-7). It is likely that Metnase
helps to resolve stalled/collapsed replication forks. In the absence of Metnase,
cells could follow alternate ways to resolve the fork, possibly through recruitment
of other factors that may have similar functions as Metnase or that promote
alternative repair mechanisms.

Based on the two observations that lack of

Metnase causes less BrdU incorporation and a delay in S-phase progression
after release from HU-induced replication stress, we conclude that Metnase
plays a role in replication fork restart after damage.
The most definitive assay revealing a role for Metnase in replication fork
restart is DNA fiber analysis. This assay allowed us to determine in more detail
whether Metnase functions in restart of stalled forks initiation, or initiation of new
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forks after damage. The DNA fiber analysis also allowed us to ask whether
Metnase affected replication fork rate. To our surprise, cells lacking Metnase
and exposed to HU for 1 h were unable to start any new forks after damage by
HU (Figures 4-8 and 4-9). Additionally, we observed a marked decrease in
restarted forks as 90% of all forks observed failed to restart. These results
indicate that Metnase plays a key role in restarting stalled forks, because the
brief HU treatment mainly causes fork stalling. In addition, when forks collapse,
restart is largely thought to be dependent on HR, an inherently slow process that
involves RAD51 replacement of RPA on ssDNA, and strand invasion of sister
chromatids by RAD51 coated DNA strands. When cells were subjected to longer
periods of replication stress, Metnase promoted resolution of γ-H2AX (Figure 410), which marks collapsed forks. This indicates that Metnase also promotes
restart of collapsed forks.
Metnase did not affect the rate of replication fork progression, even after
stress. We measured the length of DNA fibers from cells lacking Metnase,
treated with HU for 1 h, and compared them to cells containing normal levels of
the protein (Figure 4-9). Cells lacking Metnase had the same average fiber
length as the control cells under normal replication conditions, a result predicted
by our hypothesis that Metnase does not play a role in normal replication fork
progression. We did observe that fibers from cells treated with HU were shorter
than those from untreated cells, as expected, but Metnase expression level did
not affect fiber length. Thus, we conclude that Metnase does not play a role in
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the rate of replication fork progression, even under replication fork stress
conditions, once new forks are initiated or stalled forks are restarted.

5.3. Important role for Metnase in the DNA replication stress response
Metnase promotes NHEJ [139], and there are other NHEJ factors known
to promote cell survival after replication stress, including PARP-1, Ku,
Cernunos/XLF, and DNA-PK [126, 130-132, 165, 171].

NHEJ factors might

promote rejoining of DSEs at different collapsed forks, but it seems that this type
of repair would be highly inaccurate (and genome destabilizing) since each
collapsed fork produces only a single broken end. It is possible that individual
NHEJ factors promote fork restart through interactions with HR factors [172], or
through recruitment by other proteins to the fork, as suggested for PARP-1 [132].
When replication forks stall, the initial cellular response is to stabilize the
replisome to prevent fork collapse.

We know from previous work from our

laboratory and the Lee laboratory that Metnase interacts with the MRN
component Nbs1 [149]. Thus, we hypothesized that Metnase could play a role in
initial fork stabilization over a short period of replication stress, because altering
Metnase levels had an effect on the percentage of stopped forks in the DNA
fiber assay.
Metnase could stabilize or promote fork restart through its interactions
with the replisome factors PCNA and RAD9.

Although it is not yet known

whether Metnase interacts directly with these proteins or if they are in a complex
together, the fact that the Metnase SET domain has a conserved PCNA
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interacting partner (PIP) box is highly suggestive that Metnase interacts directly
with PCNA (Appendix 6.5). However, we did not observe any changes in level of
protein interaction after replication fork damage, suggesting that the functions of
these

interacting

proteins

may be regulated through post-translational

modifications such as phosphorylation or methylation. The Metnase SET domain
encodes a protein methylase, and Metnase is known to methylate histone H3
and itself [139, 146]. Metnase could regulate PCNA and/or RAD9 function by
methylating these proteins. PCNA regulates TLS through direct interactions with
TLS polymerases [117]. Thus, Metnase may enhance fork restart after UV by
enhancing TLS at UV lesions. Regardless of the specific mechanism, our results
clearly place Metnase near stalled replication forks.
RAD9 has well-established roles in the intra-S checkpoint response [115].
It is possible that Metnase could promote fork restart by influencing checkpoint
activation or downstream checkpoint-dependent processes such as inhibition of
origin firing. We investigated the effects of Metnase on checkpoint factors
downstream of RAD9, including Chk1 (discussed in more detail below). Metnase
is not required for the p53/Chk2 arm of the DNA damage checkpoint response
since replication stress-induced cell death in Metnase knockdown cells shows a
robust apoptotic response (Figure 4-3). Metnase may have a more general role
in fork restart through chromatin modification near stalled and collapsed forks. It
is noteworthy that Metnase methylates histone H3 lysine 36, which is specifically
associated with transcription [139]. Thus, Metnase could promote fork restart by
enhancing access of repair factors to stalled and collapsed forks. We have
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recently demonstrated that Metnase methylation of histone H3 promotes NHEJ
repair factor recruitment to DSBs (Appendix 6.4). Thus, Metnase may act in
similar ways at a stalled replication fork and modify histones in order to recruit
repair factors to the fork.
Alternatively, Metnase could influence fork restart through its direct
interaction with TopoIIα, another factor within the mammalian replisome [122].
TopoIIα is proposed to relax positive supercoils that form ahead of replication
forks [120].

When replication forks stall, the MCM helicase complex can

continue to unwind duplex DNA, uncoupled from the replicative polymerases,
producing excess ssDNA that is bound by RPA and triggering the intra-S
checkpoint [115, 173]. Continued DNA unwinding by MCM will also increase
positive supercoiling that may drive unusual DNA structures at stalled forks
[174].

By enhancing TopoIIα-dependent relaxation of positive supercoils,

Metnase could promote a favorable topological state that results in timely fork
restart, particularly when unusual structures form, such as replication fork
regression (chicken feet), since the resolution of such structures is probably
dependent on the topology of the stalled fork.

Local topology could also

influence restart of collapsed forks since HR-mediated invasion of broken ends
into sister chromatids requires unwinding of the sister duplex. However, when
we used TopoIIα inhibitors to test whether TopoIIα affected fork restart by DNA
fiber analysis, fiber distributions were not affected (Figures 4-13 and 4-14).
Thus, it is unlikely that the Metnase interaction with TopoIIα is important for
restarting stalled forks. These results also suggest that the Metnase role in fork
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restart is distinct from its role in promoting TopoIIα-mediated chromosome
decatenation [146]. Note that the models described above are not mutually
exclusive:

Metnase may have different roles depending on the specific

structures at stalled or collapsed replication forks, and may interact with different
proteins depending on the type of function required.

5.4. Metnase may function independent of ATM
We hypothesized that Metnase may be regulated by the DNA repair PI3
kinase ATM since Metnase is involved in replication fork re-start and this kinase
is known to be present at stalled replication forks, where it recruits and
phosphorylates other repair factors. Treatment with the ATM inhibitor KU55933
showed that cells lacking Metnase were not affected in their colony formation
abilities by the inhibition of ATM (Figure 4-16); which could suggest that
Metnase and ATM do act in the same pathway and thus no difference in colony
survival is observed when both proteins are functionally absent. Our observation
that forks were not affected by the absence of Metnase when ATM was inhibited
supports the idea that Metnase is not downstream of ATM signaling at a stalled
replication fork. Alternatively, it is possible that Metnase functions upstream of
ATM signaling and thus no differences would be observed in the DNA fiber
assay. ATM has other downstream targets that are not only important for stalled
replication fork stabilization, but also for the recruitment of replication fork repair
factors. Those proteins could be interacting or regulating Metnase recruitment or
function at a stalled replication fork. Chk1 is a protein kinase that acts
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downstream of ATR and to a lesser extent ATM, and it plays an important role in
DNA

damage

checkpoint

control

[167].

Chk1

becomes

activated

via

phosphorylation of Ser 317 in response to blocked DNA replication [168] and it
has been shown that phosphorylation at Ser 317, in conjunction with
phosphorylation of PTEN, is important for cells to reenter the cycle following
replication fork stalling [170]. We observed that phosphorylation of Chk1 at
serine 317 was diminished in the absence of Metnase. These results support the
hypothesis that Metnase regulates Chk1 as measured by Chk1 phosphorylation.
Additionally, this may explain why cells lacking Metnase have a delayed Sphase progression: in cells lacking Metnase, Chk1 is not phosphorylated at
serine-317 and cells are unable to re-enter the cell cycle after checkpoint arrest
caused by HU damage. I hypothesize that the lack of Chk1 phosphorylation is
not permanent since there are other factors, such as the MRN complex, that
activate ATM/ATR at a stalled replication fork. Additionally, we observed that
Metnase knock-down cells eventually recover from the S-phase delay, 24 h after
treatment with HU (Figures 4-5 – 4-7). Nonetheless, this observation is very
interesting and points to a potential mechanism by which Metnase may be
regulating replication fork stabilization or repair.
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5.5. PARP-1 and Metnase may function in the same pathway to repair
stalled replication forks
PARP-1 is another example of a late-evolving protein, with functions in
NHEJ and replication fork restart [132]. PARP-1 is not found in yeast, but is
present in higher eukaryotes. It recruits the ancient DNA repair endonuclease
MRE11 (a member of the MRN complex) to stalled forks, which is proposed to
process structures at the forks, leading to RPA recruitment and eventual restart
via HR. Additionally, we know that Metnase and Nbs1 (another member of the
MRN complex) interact in response to IR damage [149]. Thus, Metnase and
PARP-1 may functionally interact to promote fork restart at stalled replication
forks. Metnase knock-down increases the number of PARP-1 foci in HU-treated
cells (Figure 4-18); suggesting that Metnase helps resolve replication fork
specific PARP-1 foci. A recent paper by the Helleday laboratory places PARP-1
at stalled replication forks by DNA fiber assays and BrdU foci co-localization
[132]. Additionally, the same study demonstrated that PARP-1 mediates Mre11dependent replication fork re-start. Thus, it is possible Metnase and PARP-1
collaborate to stabilize stalled replication forks through a common target,
perhaps the MRN complex.

5.6. Limitations of this work
There are several limitations inherent in Metnase studies.

The first

limitation is that Metnase is only present in higher primates, thus it is difficult to
study it in the context of animal models, such as mice or rats. This limits the
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approach and the types of questions that can be addressed. For example, we
have yet to ask whether Metnase plays any role in embryonic development,
including bone marrow lineage determination, or cancer predisposition directly.
However, the Hromas laboratory has been able to overexpress Metnase in
mouse cells and make some interesting observations regarding chromosomal
translocations, indicating that although Metnase is not present in mice, it is
functional in mouse cells within the context of DNA DSB repair (Appendix 6.2 is
a detailed review of mechanisms of leukemia translocations and the role of
Metnase in these processes). This could open up avenues to investigate the role
of Metnase in DNA repair pathways in a system where the protein is
overexpressed. One can also imagine inducing tumors in animals and adding
Metnase protein or Metnase inhibitors to study the function of Metnase in cancer
progression and metastasis. A technical limitation of the present study is that it
was done in only three cell lines. Thus, further testing of other cells, including
primary cells, will be necessary to corroborate the observations made here.
Additionally, due to the difficulties we encountered when growing Metnase
knock-down cells and the lack of a high quality antibody against the native
protein Metnase, most of the work presented here was done using
overexpression of Metnase and in some cases using a V5-tagged version of the
protein for protein isolation and Western blot analysis. These problems are likely
to be overcome in the near future as the Hromas laboratory is producing a more
specific monoclonal antibody against Metnase, and new technologies have
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recently become available that will make the process of knocking down Metnase
much easier.

5.7. Novel contributions to the field
The work presented here has contributed to the field of DNA repair in two
ways: technical and knowledge based, both of which have advanced the field.
There are two technical contributions. First, the optimization of the adenovirus
expressing the restriction enzyme ISce-I for assays such as ChIP and HR,
without causing extensive damage to cells, will facilitate future DNA repair
studies. The Ad-ISce-I system creates a clean DSB in a consistent and
reproducible manner, comparable to the HO endonuclease used to study yeast
DSB repair. The power of this new tool is apparent in the work described in
(Appendix 6.4). In addition, the optimization of the DNA fiber assay will facilitate
studies that will lead to a better understanding of DNA. Secondly, this work adds
to the understanding of the novel protein Metnase and its role in DNA
replication. It adds a novel Metnase function in DNA replication fork repair to the
growing list of Metnase functions and offers an explanation as to how this
replication fork repair function may be regulated by identifying novel Metnase
interacting factors. This is significant because Metnase could be used as a
possible target for developing inhibitors that can be used as a cancer
chemotherapy.
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5.8. Future work
The work presented here has raised many important questions. One of
the most basic question concerns the interactions between Metnase and other
repair and replication stress response proteins. For example, does Metnase
interact directly with PCNA and Rad9? If so, what are the specific interaction
domains and how are these interactions regulated? Are there any posttranslational modifications such as phosphorylation or methylation required for
these interactions or for the “activation” or “deactivation” of these factors? It is
known that Metnase automethylates, and automethylation regulates its
functional interaction with TopoIIα-mediated chromosomal decatenation and that
it methylates other factors such as histone H3 [148]. Therefore, it is important to
study the methylase mutant produced by the Hromas laboratory to determine the
significance of the methylase in each Metnase function. Once specific interaction
domains have been identified, mutations in these domains should be analyzed in
the assays used in the present study to determine how protein-protein
interactions regulate Metnase function in the context of stalled replication forks.
Another question to address is whether Metnase acts in the same
pathway as ATM at a stalled fork, and if so, how is this regulated? Some of the
possible mutants already identified, such as the automethylation mutant, could
be used to test whether Metnase methylation activity is upstream of ATM/ATR
activation. Metnase has two potential PI3 kinase target sites that are under
investigation.

Additionally, one PI3 kinase has yet to be investigated in the

context of Metnase in replication fork stabilization, DNA-PK. Although DNA-PK is
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a well-characterized NHEJ specific kinase, there is new evidence that DNA-PK
may also play a role in replication fork stabilization, and that this function may be
related to PARP-1 [132]. The Helleday laboratory has already demonstrated that
cells lacking DNA-PK show a similar, though less severe, replication fork restart
defect to compared Metnase knock-down cells. It would be interesting to
investigate whether a lack of Metnase would further prevent DNA-PK -/- cells
from stabilizing a stalled replication fork (see Appendix 6.3 for details on DNAPK and stalled replication forks, Fig 7). Another question to address is whether
Metnase is directly phosphorylated by any of these kinases. ATM, ATR and/or
DNA-PK may directly or indirectly regulate Metnase at stalled or collapsed
replication forks.
Our preliminary results showed that cells lacking Metnase were unable to
resolve PARP-1 foci after damage by HU. It will be interesting to determine
whether this phenotype is HU specific or whether other DNA replication fork
stressors, such as UV and CPT, would have a similar effect. Additionally, it
would be interesting to determine if lack of Metnase augments the PARP-1 -/phenotype observed by the Helleday laboratory as well. Does Metnase
methylate PARP-1 as a way to regulate PARP-1 activity? If so, how is this
modification regulated? Is there a direct interaction between PARP-1 and
Metnase? Are the roles of Metnase and PARP-1 in replication fork stabilization
related to their respective roles in NHEJ? This seems unlikely because Metnase
and PARP-1 do not function in the same type of NHEJ pathway. Metnase
functions in classical NHEJ while PARP-1 is thought to be part of the alternative
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NHEJ pathway. However, during replication, it is possible that they work together
in order to facilitate faster repair, perhaps by enhancing recruitment of other
repair factors.
One very interesting issue, but technically demanding to address, is
protein dynamics at a stalled replication fork: What factors are present, how
quickly are they recruited, and how long are they retained? This would be best
addressed by using Chromatin immunoprecipitation (ChIP) of various proteins at
stalled replication forks. Dr. Sheema Mir in the Hromas lab, was able to detect
NHEJ factor recruitment to a specific DSB site and characterize the kinetics of
recruitment, and how this is regulated by Metnase’s methylation of histone H3,
using the Ad-ISce-I system I optimized (Appendix 6.4). It is possible that
Metnase plays a similar role at stalled replication forks. Thus, Metnase may be
recruited to stalled forks, and through methylation of histone H3 or other
proteins, promote recruitment of proteins necessary for signaling and/or repair of
the damage. I predict that this function of Metnase would be backed-up by
another, slower mechanism since the replication phenotype, although severe in
the short term, seems to be resolved within hours.

89

5.9. Concluding remarks
Prior studies have established that Metnase is highly expressed in
actively proliferating tissues [139]. It has recently been shown that Metnase is
frequently

overexpressed

in

leukemia

cell

lines

compared

to

normal

counterparts. Importantly, downregulating Metnase greatly enhances tumor cell
sensitivity to common chemotherapeutics including epididophylotoxins and
anthracyclines [147, 148]. The current study establishes Metnase as a critical
factor in the replication stress response.

Metnase is therefore an excellent

target for therapeutic strategies that block DNA synthesis, or that exploit defects
of tumor cells in replication fork restart [175, 176], and it may prove to be an
important target in the treatment of a wide variety of tumor types.
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Figure 5-1. Potential roles of Metnase in the replication stress response.
We have shown here that Metnase interacts with PCNA and 9-1-1
component Rad9. Additionally, Metnase interacts with TopoIIα and stimulates
relaxation of positively supercoiled DNA ahead of the replication fork. Previous
work from our laboratory demonstrated that Metnase enhances chromosomal
decatenation (behind the replication fork).
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Histone methylation can alter chromatin configuration, and thereby
regulate many essential cellular functions, including transcription,
replication, genome stability, and apoptosis, epigenetically coding for cell
behavior1. Such methylation regulated by histone methylases, usually
sharing a SET motif, and demethylases, usually sharing a Jumonji
domain2,3. Histone methylation has been hypothesized to play an important
role in DNA double-strand break (DSB) repair, the most genotoxic type of
DNA damage4-6. Previously described histone methylation events related to
DNA repair are not induced by DNA damage7-9, and therefore other histone
modifications that might code for DNA damage have been sought. We
surveyed histone 3 dimethylation events for induction by radiation, which
produces DNA DSBs, and found that histone 3 lysine 36 dimethylation
(H3K36me2) was the only such event induced. Non-homologous endjoining (NHEJ) is the major mammalian DSB repair pathway10,11. The NHEJ
DNA repair factor Metnase has a SET domain that dimethylates H3K3612.
Using a human cell system that rapidly generates a single defined DSB in
the vast majority of cells, we found that Metnase rapidly localized to DSBs,
and directly mediated the local formation of H3K36me2. H3K36me2 was
found to interact with the early NHEJ repair components NBS1, MRE11, and
Ku70, after DSB formation, and its presence at the induced DSB was
correlated with the concentration of these early repair components at
DSBs. An H3K36 demethylase has recently been described, the Jumonji
(JmjC) domain protein JHDM1a (also FBXL11), and this was found to
reduce the presence of H3K36me2 at a single DSB, and repress DSB repair,
by inhibiting Metnase’s ability to induce H3K36me2. Thus, these
experiments reveal a cognate histone methylase/demethylase pair that
defines a histone code for NHEJ repair.
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Given that histone methylation can regulate genomic stability, its role in DNA
repair has been widely pursued. There is some evidence that histone
methylation may indeed play a role in DNA repair. The DSB repair component
53BP1 is recruited to sites of damage by methylated histone 3 lysine 79 (H3K79) and
histone 4 lysine 20 (H4K20)7-9. However, neither H3K79 nor H4K20 methylation is induced
by DNA damage9 (also supplementary Fig. 1), so another histone methylation event coding
for DNA damage has been sought.

We used western blot analysis to survey H3 dimethylation changes formed after induction of
DSBs by γ-rays. This analysis revealed that the major immediate H3 dimethylation event
was H3K36me2, which was induced up to 14-fold within 15 min after radiation-induced DSB
formation (Fig. 1A, Supplementary Figs. S1, S2). This led us to hypothesize that a specific
SET domain protein mediated this methylation event. We focused on the NHEJ DNA

repair factor Metnase, which has a SET domain that dimethylates H3K36,
improves survival after γ-ray exposure12, and is recruited to sites of DNA
damage

13,14

. To test whether H3K36me2 was associated with DSB formation

and repair, and whether Metnase could mediate this methylation event, we
generated a model human cell system that allowed rapid induction of a single
DSB within a defined, unique sequence that would preferentially be repaired by
NHEJ. We engineered a human sarcoma cell line, termed HT1904, to contain a
unique I-SceI site in a single puromycin acetyltransferase (puro) gene sequence,
which does not share homology with any other sequence in the genome
(Supplementary Fig. S3). Using adenoviral-mediated transduction of the gene
encoding I-SceI endonuclease, 90% of cells generated a single DSB within 60
min (Supplemental Fig. S4A)

15-17

. If DSBs were induced in the puro sequence

after DNA replication, homologous recombination repair could occur between
sister chromatids, but this is unlikely because DSBs would usually occur in both
sister chromatids.

Thus, repair of the DSB induced by I-SceI will be predominantly by the NHEJ
pathway, and the kinetics of DSB repair can measured using quantitative real129

time PCR (q-RT PCR). Consistent with its known ability to enhance NHEJ
repair12,13, over-expression of Metnase increased by up to 4-fold the amount of
re-ligated DNA analyzed with PCR primers spanning the I-SceI site
(Supplementary Fig. S4B, see also Fig. 4B). The recruitment of proteins such as
H3K36me2 and Metnase to this DSB can be detected by chromatin
immunoprecipitation (ChIP) analysis and quantified by q-RT PCR. Functional
ChIP primer targets were identified within one nucleosome (152 nt) of the I-SceI
site to monitor events immediately adjacent to the DSB (Supplementary Table 1).

Using the HT1904 system, we used ChIP to determine whether H3K36 was
dimethylated at the induced DSB (Fig. 1B, Supplementary Fig. S5). H3K36me2
was not present at the region adjacent to the I-SceI site before DSB induction,
but it was markedly induced within 1 h of DSB induction and was maintained for
at least 8 h, and then declined over a 24-42 h period of repair. Other H3
methylation events were detected at the DSB by ChIP analysis to a far lesser
extent than H3K326me2 (Fig. 1B). H3K36me2 was only detected adjacent to the
DSB; it was barely detected at a site 650 bp from the DSB (not shown). Next, we
tested whether the H3K36 methylase Metnase was also present adjacent to the
induced DSB by ChIP analysis in the HT1904 system. We found that Metnase
was recruited to the DSB with very similar kinetics to the induction of H3K36me2,
and that Metnase recruitment to the DSB was increased in HT1904 cells
overexpressing Metnase, and decreased when Metnase levels were decreased
by siRNA (Fig. 1C, Supplementary Fig. S5). Since H3K36me2 and Metnase
were indeed both present at the induced DSB, we tested whether altering
Metnase levels could affect the formation of H3K36me2 at the DSB site.
Increasing Metnase levels indeed enhanced the formation of H3K36me2 at the
DSB region while repressing Metnase had the opposite effect (Fig. 1D),
suggesting that Metnase is responsible for H3K36 dimethylation at DSBs.
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However, it was possible that H3K36 dimethylation only correlated with the
presence of Metnase, but was not caused by it, so we next analyzed whether the
D248S SET domain mutant of Metnase, which fails to promote NHEJ12 (also Fig.
4c), was also deficient in H3K36 dimethylation at DSBs. Unlike wild-type
Metnase, the D248S Metnase mutant did not induce H3K36me2 at the DSB (Fig.
1E), indicating that H3K36 dimethylation at DSBs is directly caused by Metnase .
H3K36me2 correlates with the maintenance of intra-genic transcription18,19, but
the mechanism by which it promotes NHEJ was unclear.
Since there is evidence that 53BP1 is recruited to DNA DSBs by methylated
7-9
histones , we postulated that H3K36me2 might similarly recruit repair

components to DSBs. We again induced the formation of H3K36me2 with γrays, immunoprecipitated H2K36me2, and then analyzed the immunoprecipitate
for the presence of early NHEJ factors (Fig. 2). We found that components of
the MRE11-RAD50-NBS1 DSB sensor complex, and Ku70, an NHEJ factor that
binds to DNA ends at DSBs10,11, were all present in the H3K36me2
immunoprecipitate, and the association of these early NHEJ factors with
H3K36me2 appeared to be induced by radiation. However, the late NHEJ factor
10,11

DNA Ligase IV

, was not detected in the H3K36me2 immunoprecipitate. In

addition, 53BP1 was not detected in the H3K36me2 immunoprecipitate,
consistent with its recruitment by other methylated histones7-9. Based on these
findings, we examined whether Metnase levels regulated the recruitment of
MRE11, phosphorylated NBS1 (a product of ATM kinase activity), and Ku70 to
the region adjacent to an induced DSB by ChIP in HT1904 cells. We found that
increasing Metnase enhanced the recruitment of each of these repair
components to the DSB , and repressing Metnase levels decreased their
recruitment (Fig. 3).
JHDM1a has been identified as a H3K36 demethylase20,21. Conserved across
species, JHDM1a specifically demethylates H3K36me2 in vitro and in vivo.
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Thus, JHDM1a was an intriguing candidate as a regulatory partner to Metnase
during the DSB-induced histone modifications described here. We examined
whether over-expression of JHDM1a could alter the presence of H3K36me2 at
the induced DSB in HT1904 cells. Increasing the expression of JHDM1a in
HT1904 cells dramatically reduced the formation of H3K36me2 at the induced
DSB site (Fig. 4A, Supplementary Fig. S8). Moreover, JHDM1a over-expression
also blocked the ability of Metnase to induce H3K36me2 at the DSB site. These
changes in H3K36 dimethylation have significant functional consequences as
over-expression of JHDM1a prevented Metnase from enhancing DSB repair in
the HT1904 system (Fig. 4B, D), similar to the D248S Metnase mutant (Fig. 4C),
implying that Metnase promotes NHEJ capability through methylation of H3K36.
Thus, JHDM1a opposes the effect of Metnase on DSB induced H3K36
methylation and DSB repair by NHEJ. It is possible that JHDM1a could serve to
negatively regulate NHEJ repair during the cell cycle, however it is more likely
that it restores chromatin to its native state after DSB repair.

In this study we have identified: 1) a histone code for DNA DSB damage,
H3K36me2; 2) the cognate histone 3 methylase/demethylase regulatory pair that
mediates the formation and removal of this code; and 3) a role for H3K36me2 in
recruiting early NHEJ components to DNA adjacent to DSBs Thus, H3K36me2
has a place alongside phosphorylated H2Ax and ubiquitylated H2A as DNA
damage-induced histone modifications that recruit repair components and
enhance repair

22-26

. Given that H3K36me2 is detected near DSBs soon after

DSB induction, and that H3K36me2 co-immunoprecipitates with early NHEJ
components, it is possible that H3K36me2 dimethylation catalyzes an early
cascade of repair events at DSBs. Alternatively,, H3K36me2 may stabilize early
NHEJ repair factors at the DSB, after their recruitment by free DNA ends. While
JHDM1a may initially inhibit H3K36me2 formation, it may ultimately complete
repair by removing this dimethyl tag at the DSB site, and perhaps enhance
release of repair components from that site. With its early role in chromatin
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regulation of DSB repair, and evidence that high Metnase levels may mediate
clinical resistance to radiation or chemotherapy, Metnase is an attractive target
for enhancing tumor response to these modalities27,28.

Methods
Full Methods accompany this paper in supplementary information on-line.

REFERENCES

1.

Trievel, R.C. Structure and function of histone methyltransferases. Crit

Rev Eukaryot Gene Expr. 14,147-69 (2004).
2.

Agger, K., Christensen, J., Cloos, P.A., & Helin, K. The emerging

functions of histone demethylases. Curr Opin Genet Dev. 18, 159-68 (2008).
3.

Lan, F., Nottke, A.C., & Shi, Y. Mechanisms involved in the regulation of

histone lysine demethylases. Curr Opin Cell Biol. 20, 316-25 (2008).
4.

Peng, J.C., Karpen, G.H. Heterochromatic genome stability requires

regulators of histone H3 K9 methylation. PLoS Genet. 5, e1000435 (2009).
5.

Muñoz, I.M., & Rouse, J. Control of histone methylation and genome

stability by PTIP. EMBO Rep. 10, 239-45 (2009).
6.

Oda, H., et al. Monomethylation of histone H4-lysine 20 is involved in

chromosome structure and stability and is essential for mouse development. Mol
Cell Biol. 29, 2278-95 (2009).
7.

Botuyan, M.V., et al. Structural basis for the methylation state-specific

recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell 127,
1361-73 (2006).
8.

Sanders, S.L., et al. Methylation of histone H4 lysine 20 controls

recruitment of Crb2 to sites of DNA damage. Cell. 119, 603-14 (2004).
9.

Huyen, Y., et al. Methylated lysine 79 of histone H3 targets 53BP1 to DNA

double-strand breaks. Nature 432, 406-11 (2004).
133

10.

Hartlerode, A.J., & Scully, R. Mechanisms of double-strand break repair in

somatic mammalian cells. Biochem J. 423, 157-68 (2009).
11.

Pardo, B., Gómez-González, B., & Aguilera, A. DNA repair in mammalian

cells: DNA double-strand break repair: how to fix a broken relationship. Cell Mol
Life Sci. 66, 1039-56 (2009).
12.

Lee, S.H., et al. The SET domain protein Metnase mediates foreign DNA

integration and links integration to nonhomologous end-joining repair. Proc Natl
Acad Sci U S A 102, 18075-80 (2005).
13.

Roman, Y., et al. Biochemical characterization of a SET and transposase

fusion protein, Metnase: its DNA binding and DNA cleavage activity.
Biochemistry 46, 11369-76 (2007).
14.

Beck, B.D., Park, S.J., Lee, Y.J., Roman, Y., Hromas, R.A., & Lee, S.H.

Human Pso4 is a Metnase (SETMAR)-binding partner that regulates Metnase
function in DNA repair. J Biol Chem. 283, 9023-30 (2008).
15.

Golding, S., et al. Double strand break repair by homologous

recombination is regulated by cell cycle-independent signaling via ATM in
human glioma cells. J. Biol. Chem. 279, 15402–15410 (2004).
16.

Anglana, M. & Bacchetti, S. Construction of a recombinant adenovirus for

efficient delivery of the I-SceI yeast endonuclease to human cells and its
application in the in vivo cleavage of chromosomes to expose new potential
telomeres. Nucleic Acids Res. 27, 4276-4281 (1999).
17.

Valerie, K., et al. Improved radiosensitization of rat glioma cells with

adenovirus-expressed mutant herpes simplex virus thymidine kinase in
combination with acyclovir. Cancer Gene Therapy 7, 879–884 (2000).
18.

Rao, B., Shibata, Y., Strahl, B.D., & Lieb, J.D. Dimethylation of histone

H3 at lysine 36 demarcates regulatory and nonregulatory chromatin genomewide. Mol Cell Biol. 25, 9447-59 (2005).
19.

Morris, S.A., et al. H3 K36 methylation is associated with transcription

elongation in Schizosaccharomyces pombe. Eukaryot Cell 4, 1446-54 (2005).
134

20.

Anand, R., & Marmorstein, R. Structure and mechanism of lysine-specific

demethylase enzymes. J Biol Chem. 282, 35425-9 (2007).
21.

Tsukada, Y., et al. Histone demethylation by a family of JmjC domain-

containing proteins. Nature 439, 811-6 (2006).
22.

Escargueil, A.E., Soares, D.G., Salvador, M., Larsen, A.K., & Henriques,

J.A. What histone code for DNA repair? Mutat Res. 658, 259-70 (2008).
23.

Sedelnikova, O.A., Pilch, D.R., Redon, C., & Bonner W.M. Histone H2AX

in DNA damage and repair. Cancer Biol Ther. 2, 233-5 (2003).
24.

Huen, M.S., et al. RNF8 transduces the DNA-damage signal via histone

ubiquitylation and checkpoint protein assembly. Cell 131, 901-14 (2007).
25.

Sobhian, B., et al. P80 targets BRCA1 to specific ubiquitin structures at

DNA damage sites. Science 316, 1198-202 (2007).
26.

Kim, H., Chen, J., & Yu, X. Ubiquitin-binding protein RAP80 mediates

BRCA1-dependent DNA damage response. Science 316, 1202-5 (2007).
27.

Wray, J., et al. Metnase mediates chromosome decatenation in acute

leukemia cells. Blood 114, 1852-8 (2009).
28.

Wray, J., et al. Metnase mediates resistance to topoisomerase II

inhibitors in breast cancer cells. PLoS One 4, e5323 (2009)

Acknowledgements: The authors gratefully acknowledge the support of NIH
R01 GM084020 (J.A.N.), R01 CA100862 (J.A.N.), an APRC supplement to
CA100862 (J.A.N. and R.H.), NIH R01 CA102283 (R.H.), NIH R01 HL075783
(R.H.), NIH RO1 CA139429 (R.H.), and the Leukemia and Lymphoma Society
SCOR 7388-06 (R.H.).

Author Contributions: S.F., E.W., and J.W. designed and performed
experiments, L. D. H. and M. B. generated essential reagents, S.-H. L. analyzed
data and wrote the manuscript, J.A.N. designed experiments, analyzed data and
135

wrote the manuscript, and R.H. conceived of the project, designed experiments,
analyzed data and wrote the manuscript.

FIGURE LEGENDS
Figure 1. Dimethylation of H3K36 by Metnase at DSBs. A, Western analysis
demonstrating that H3K36me2 is induced rapidly after exposure to γ-rays (8 Gy).
B, Time course ChIP analysis of methylated H3 species quantified by real time
PCR adjacent to a single induced DSB. There was no detectable methylated H3
prior to DSB induction. For all ChIP experiments, each time point is the average
of three measurements repeated at least twice, normalized to GAPDH. C, ChIP
analysis of Metnase adjacent to a single induced DSB. There was no detectable
Metnase prior to DSB induction. D, ChIP analysis demonstrating that Metnase
levels alter H3K36me2 formation adjacent to a DSB. There was no detectable
H3K36me2 at the DSB region prior to DSB induction. E, Overexpression of the
Metnase D248S SET domain mutant does not induce H3K36me2 formation at a
DSB.

Figure 2. Co-Immunoprecipitation of DNA repair factors with H3K36me2.
Immunoprecipitation of H3K36me2 was performed in HT1904 cells mock treated
(C), or 15 and 60 min after 10 Gy γ-ray exposure.

Figure 3. ChIP analysis of early DNA repair factors at a single induced
DSB. Increasing Metnase levels enhances recruitment of Ku70 (A),
phosphorylated NBS1 (B), and MRE11 (C) to a DSB, while repressing Metnase
reduced recruitment of these factors. These proteins were not detectable
adjacent to the DSB site prior to DSB induction.

Figure 4. The JHDM1a histone demethylase counteracts Metnase histone
methylase and DSB repair activities. A, ChIP analysis in cells
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overexpreressing JHDM1a show reduced H3K36me2 near a DSB, and JHDM1a
overexpression blocks the effect of overexpressed Metnase on H3K36me2
formation (compare with Fig. 1D and 1E). B, Over-expression of Metnase
enhances DSB repair, as measured by reduced amount of unligated I-SceI PCR
product (see also Supplementary Fig. S4B). Repressing Metnase slows DSB
repair. C, Over-expression of the Metnase D248S SET domain mutant
decreased repair . D, Over-expression of JHDM1a blocked the ability of
overexpressed Metnase to promote DSB repair (compare with panel B).

137

Figure 1
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Figure 3
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Figure 4
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Supplementary Methods
Cell lines- HT1904 cells were derived from the human sarcoma cell line HT1080
by stably transfecting a linearized vector containing the puro gene with the
phosphogylcerol

kinase

promoter,

and

containing

an

I-Sce-I

site

(TGGTTCCTGGATTACCCTGTTATCCCTACGCGCCGGGG, with the I-SceI
site in bold italics flanked by puro sequence). This vector also contained a
blasticidin resistance cassette for selection. HT1904 cells were cloned from a
single blasticidin resistant colony, and Southern analysis was used to determine
that there was a single integrated puro sequence (Supplemental Fig. S3).
HT1904 cells and its derivatives with altered Metnase or JHDM1a expression
levels were cultured in DMEM with 10% heat-inactivated fetal calf serum
supplemented with antibiotics and anti-fungal agents. HT1904 express Metnase
at moderate levels, making them amenable to both over- and underexpression.
HEK-293T cells, which do not express Metnase, were transfected with a pcDNAMetnase to overexpress Metnase, or with empty pcDNA vector as control.

I-SceI adenovirus generation, quantification and transduction- Adenovirus
17
expressing I-sceI was a kind gift from K. Valerie . The virus was propagated

using AD293 cells as previously described16-18. Briefly, cells were washed with
PBS, and then 5mL of OptiMEM (Invitrogen, Carlsbad, CA) containing 10 viral
0
particles per cell was added, and cells were incubated at 37 C for 2 h, then 10

mL of DMEM containing 10% serum (Thermoscientific, Waltham, MA) and 1%
penicillin/streptomycin (Invitrogen) was added. Cells were incubated for 4 days,
collected and centrifuged at 8000 rpm for 10 min at 40C, and supernatant was
removed. The cell pellet was subjected to 5 snap-freeze cycles using
methanol/dry ice, then centrifuged at 3000 rpm for 30 min at 40C. The
supernatant was purified using cesium chloride density gradient centrifugation at
0
32000 rpm at 10 C for 22 hours. The virus was stored in virus storage buffer (20

mM Tris-HCl pH 8, 4mM MgCl, 10% sucrose) at -800C. Quantification was done
using the protocol outlined in the adEasy manual (Qbiogene, Carlsbad, CA).
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We routinely obtained viral titers of 3 x 109 viral particles/μL. HT1904 cells were
exposed to the I-SceI adenovirus at an MOI of 1000 (Supplementary Fig. S4) for
3 h, and then washed three times in media to remove the adenovirus. For all
experiments using adenoviral I-SceI transduction, time 0 was before infection
with adenovirus and subsequent time points were measured after adenovirus
removal. At the time of viral media removal, no cells had the ISce-I site cleaved,
but within 60 minutes after adenovirus removal, ~90% of the cells had the puro
sequence cleaved as analyzed by real time PCR with primers spanning the ISceI site (Supplementary Fig. S4B).

Manipulation of Metnase and JHDM1a expression- Cells over-expressing V5tagged Metnase were generated by electroporation with pCDNA-Metnase
(neomycin selectable), and cells under-expressing Metnase were generated by
electroporation with U6-siRNA Metnase (hygromycin selectable) as previously
described12,27,28. Controls were transfected with empty pcDNA or a U6 vector
that expresses an siRNA targeted to GFP siRNA. JHDM1a was overexpressed
by transfection of a pCMV-JHDM1a vector (Open Biosystems, ThermoFisher
Scientific, Pittsburgh, PA), with empty vector as control. Metnase and JHDM1a
protein levels were assessed by Western analysis with anti-Metnase or antiJHDM1a antiserum normalized to actin as described12 for each experiment
(Supplementary Fig. S7). To prepare cell extracts for Western analysis, cells
were briefly washed with phosphate-buffered saline and lysed in a buffer
containing 25 mm HEPES (pH 7.5), 0.3 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA,
0.5% Triton X-100, 20 mM β-glycerolphosphate, 1 mM sodium vanadate, 1 mM
dithiothreitol, and protease inhibitor cocktails (Sigma). Cell lysates (50 μg) were
separated by SDS-PAGE, and the proteins were transferred to a PVDF
membrane (Millipore, Billerica, MA) and immunoblotted with primary antibody
followed by peroxidase-coupled secondary antibody (GE Healthcare, UK) and
detected by enhanced chemiluminescence (West Pico Supersignal reagent;
Thermo Fisher Scientific, Pittsburgh, PA) and visualized on Kodak X-Omat film.
142

RNA Extraction and Amplification
Total RNA was extracted using an RNA-Easy kit (Qiagen, Germany). One
microgram of total RNA was reverse transcribed using SuperScript III and
random hexamers (Invitrogen).

PCR reactions were performed with primers

listed in Supplementary Table 1.
Co-Immunoprecipitation

HT1904 cells were treated with 10 Gy of γ-rays and allowed to recover for 15 min
or 60 min. Total protein lysates were prepared as above at each time point as
well as from untreated HT1904 cells. Protein lysates were immunoprecipitated
with H3K36me2 antibody (Cell Signaling, Danvers, MA) and protein A/G (1:1)
agarose beads (Calbiochem) overnight at 4oC. The agarose beads were gently
pelleted and washed three times with lysis buffer and three times with cold PBS.
The beads were resuspended in lysis buffer and the proteins were analyzed by
Western blotting using the following primary antibodies: anti-H3K36me2, antiphospho-Nbs1(Ser343), anti-Nbs1 (from Cell Signaling, Danvers, MA); antiMre11, anti-Ku70 (from BD Biosciences, San Jose, CA); anti-53BP1 (Abcam,
Cambridge, MA); anti-Rad50 (Genetex, Irvine, CA); or anti-DNA Ligase IV
(Genway, San Diego, CA).
ChIP analysis
ChIP was performed was using primer pairs 152 bp and 650 bp from the I-SceI
site. ChIP was performed before I-SceI adenovirus infection and at 0.5, 1, 2, 4,
8, 24, 42 hours after removal of the I-SceI adenovirus. Triplicate plates of 107
exponentially growing HT1904 cells per experimental condition per time point
were washed with PBS and incubated for 10 min with 1% formaldehyde; after
quenching the reaction with 0.125 M glycine, cells were harvested and pelleted.
Pellets were resuspended in 2 ml lysis buffer (0.1 M PIPES pH 8, 1 M KCl, 10%
NP-40), incubated on ice for 30 min, and dounced 10 times. Nuclei were
pelleted for 10 min at 4°C, resuspended in 1 ml of nuclear lysis buffer without
EDTA (50 mM Tris–HCl, pH 8, 0.5% deoxycholic acid). Digestion was performed
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with 40 U of micrococcal nuclease (MNase I, New England Biolabs) at room
temperature for 15 min, and then stopped by placing the reaction at 4°C, and
adding EDTA to a final concentration of 20 mM. ChIP assays were performed
with 3 μg of the following antibodies: anti-Metnase12, anti-histone H3K36me2
(Cell Signaling), anti-XRCC4 (Abcam), anti-Mre11 (Abcam), anti-Ligase IV
(Sigma, St Louis, MO), anti-histone 3 (Cell Signaling), anti-KU 80 (Cell
Signaling), anti-phospho NBS1 (ser343, Cell Signaling), anti-NBS1 (Cell
Signaling), anti-phospho H2Ax (Millipore, Billerica, MA), anti-H3K79me2
(Millipore), anti-H3K9me2 (Cell Signaling), anti-H3K4me2 (Cell Signaling), and
anti-H3K27me2 (Cell Signaling). Chromatin crosslinks were reversed by adding
NaCl to a final concentration of 0.3 M followed by incubation at 65°C overnight
with RNase A (10 μg/μl), then at 50°C for 3 hours with Proteinase K. Finally, the
DNA was purified using Qiagen purification kit and visualized on a 2% agarose
gel. DNA associated with immunoprecipitated protein was then quantified using
real time PCR.

Real-time PCR
Quantitative real-time PCR was performed using SYBR green reagent (Applied
Biosystems, USA) with an ABI PRISM 7000 Sequence Detection System.
Primers were designed to amplify genomic regions of 120–180 bp in size
(Supplementary Table 1). All experimental values were normalized to the input
DNA using amplification of GAPDH (Supplementary Table 1).
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Supplementary Figure legends
Figure S1- Survey of H3 dimethylation after ionizing radiation. Western
analysis of 5 different H3 dimethylation sites in samples isolated before (C) or
indicated times after 10 Gy γ-ray exposure.

Figure S2- Metnase overexpression enhances H3K36me2 formation after
ionizing radiation. Western blot analysis of HEK-293T cells transfected with
pcDNA or pcDNA-Metnase and irradiated with 10 Gy γ-rays. Proteins extracts were
prepared * h after irradiation and analyzed by Western blot.

Fig. S3. Schematic of the vector stably transduced into HT1080 human sarcoma
cells to generate a cell line with a single I-SceI site in a unique sequence. The
locations of the I-SceI site and the ChIP primer sets 152 and 604 bp from the ISceI site are shown.

Figure S4- Analysis of DSB induction. (A) q-RT PCR analysis of the PCR
product product using primers spanning the I-SceI site. Plotted are relative
values calculated as the inverse of the total amount of amplified puro DNA
compared to input GAPDH DNA for I-SceI adenovirus MOIs of 100 and 1000.
(B) Schematic of PCR primers spanning the I-SceI site and agarose gel analysis
of PCR products from samples isolated 1-24 h after I-SceI adenovirus
transduction.

Figure S5- ChIP analysis with primers 152 bp from the I-SceI site of H3K36me2
(left) or Metnase (right) from samples collected before (C), and 2 or 4 h after ISceI adenovirus transduction in cells expressing normal (pcDNA and U6), high
(pcDNA-Metnase) or low levels of Metnase.

Figure S6- Time course of I-SceI expression. Cells were collected before (C) or
at indicated times after I-SceI adenovirus transduction, total RNA was isolated
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and subjected to RT-PCR analysis by amplifying I-SceI mRNA or 18S rRNA as
loading control.

Figure S7- Metnase expression levels are stable throughout the 42 h time
course. Western blot analyses of Metnase, with actin as loading control, were
performed in HT1904 derivatives expressing Metnase at normal (pcDNA and
U6), high (pcDNA-Metnase) or low (U6-siRNA-Metnase) levels. Control lanes
(C) show normal expression, and remaining lanes are from samples isolated at
indicated times after I-SceI adenovirus transduction.

Fig. S8.

Western analysis of JHDM1a expression. HT1904 cells transfected

with pCMV-JHDM1a vector or empty pCMV vector were analyzed by Western
blot using anti-JHDM1a antibodies with actin as loading control.
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Figure S1

Figure S2
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Figure S3

Figure S4

‘
Figure S5
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Figure S6

Figure S7

Fig. S8
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Table 1
Primer Name

Sequence (5’ – 3’)

I-SceI Forward

CCCGGCTGCCCGCGCAGCAAC

I-SceI Reverse

TTGCGGGGCGCGGAGGTCTCCA

152 Forward

TACGCACCCTCGCCGCCGCGTTCG

152 Reverse

TGCGCGGGCCGATCTCGGCGA

650 Forward

AGCAGCCCCGCTGGCACTTGGCGC

650 Reverse

CTCAGCGGTGCTGTCCATCTGCAC

GAPDH Forward

TCGGTTCTTGCCTCTTGTC

GAPDH Reverse

CTTCCATTCTGTCTTCCACTC
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6.5. Summary of PIP containing proteins and their functions.
Table 6-1. Conserved PIP boxes in Metnase and other human DNA
repair/metabolism proteins.

Protein
Metnase
PARP-1
DNMT1
DNA Polβ
p66
MYH
UNG2
XPB
BLM
RECQL5β
p15 PAF
ING1b
MDM2
WSTF

Function(s)
NHEJ, decatenation, fork
restart
DNA repair, fork restart
DNA methyltransferase
DNA repair polymerase
DNA polδ subunit
BER glycosylase
BER glycosylase
NER endonuclease
DNA repair helicase
DNA repair helicase
Cell growth promotion
Apoptosis
E3 ubiquitin ligase
Chromatin remodeling

Consensus PIP box:

PIP box*
(119) VVQKGLQ-FH

Reference
[139]

(668) PVQDLIKMIF
(162) TRQTTITSHF
(215) VEQLQKV-HF
(454) NRQVSITGFF
(521) MGQQVLDNFF
(2)
IGQKTLYSFF
(988) QTQLRIDSFF
(81) TNQQRVKDFF
(962) EAQN-LIRHF
(60) KWQKGIGEFF
(7)
GEQLHLVNY
(481) PIQMIVLTYF
(662) LLQDEIAEDY
(1024)RYQDIIHSIH
(1099)ALQASVIKKF
(1432)TEQCLVALLH
[K-A]QxxI/L/Vxx(F/Y/H/W) 2

[177]
[178]
[179]
[180]
[181]
[182]
[183]
[184]
[184]
[185]
[186]
[187]
[188]

[117]

*All proteins have the core PIP Q-I/L/V motif, and nearly all (including Metnase)
have the C-terminal pair of F/Y/H residues (shown in red). Many PIP boxes
have upstream K and/or A residues; Metnase, and PARP-1 have conservative
substitutions (V for A) at this position, indicated in green.

151

6.6. Metnase Promotes Restart of Stalled and Collapsed Replication Forks
Authors: Leyma P. De Haro*, Justin Wray*, Elizabeth A. Williamson,
Stephen T. Durant, Lori Corwin, Amanda C. Gentry, Neil Osheroff, Suk-Hee
Lee, Robert Hromas, and Jac A. Nickoloff
(in revision for publication to Nucleic Acids Research)

Metnase Promotes Restart of Stalled and Collapsed Replication Forks
Leyma P. De Haro1*, Justin Wray2*, Elizabeth A. Williamson2,
Stephen T. Durant1, Lori Corwin2, Amanda C. Gentry3, Neil Osheroff3, Suk-Hee
Lee4, Robert Hromas2, and Jac A. Nickoloff1†
1

Department of Molecular Genetics and Microbiology, Cancer Research and
Treatment Center, University of New Mexico School of Medicine, Albuquerque,
NM, 87131, USA
2

Division of Hematology-Oncology, Cancer Research and Treatment Center,
University of New Mexico School of Medicine, Albuquerque, NM 87131, USA
3

Departments of Biochemistry and Medicine, Vanderbilt University School of
Medicine, Nashville, TN 37232-0146, USA

4

Department of Biochemistry and Molecular Biology, Indiana University School of
Medicine, Indianapolis, IN 46202- 5122, USA

*These authors contributed equally to the work.
Keywords: DNA damage, hydroxyurea, DNA fiber analysis, genome stability
Running Title: Metnase Promotes Replication Fork Restart
†

Address correspondence to (present address): Jac A. Nickoloff, Department of
Environmental and Radiological Health Sciences, Colorado State University, Ft.
Collins, CO 80523, USA Tel. 970-491-6674; Fax 970-491-0623; Email
J.Nickoloff@colostate.edu

152

ABSTRACT
Metnase is a recently evolved human protein with methylase (SET) and
nuclease domains that is widely expressed, especially in proliferating
tissues. Metnase interacts with DNA ligase IV, promotes non-homologous
end-joining (NHEJ), and knockdown causes mild hypersensitivity to
ionizing radiation. Metnase also promotes plasmid and viral DNA
integration, and topoisomerase IIα (TopoIIα)-dependent chromosome
decatenation. NHEJ factors have been implicated in replication stress
response, and TopoIIα has been proposed to relax positive supercoils in
front of replication forks. Here we show that Metnase promotes cell
proliferation, but it does not alter cell cycle distributions, or the speed of
replication fork progression. However, Metnase knockdown greatly
sensitized cells to replication stress induced by hydroxyurea, UV light, and
the topoisomerase I poison camptothecin, and conferred a marked defect
in restart of stalled replication forks. Metnase also promotes resolution of
phosphorylated histone H2AX, a marker of DNA double-strand breaks at
collapsed forks, and it co-immunoprecipitates with PCNA, and RAD9, a
member of the PCNA-like RAD9-HUS1-RAD1 complex that has key roles in
the intra-S checkpoint. Metnase also promotes TopoIIα-mediated
relaxation of positively supercoiled DNA. Together these results establish
Metnase as a key factor that promotes restart of both stalled and collapsed
replication forks.
INTRODUCTION
Cellular systems that maintain genome stability are critical for cancer
suppression. The failure to accurately repair DNA damage, including singlestrand damage and double-strand breaks, is strongly linked to cancer initiation
and progression. DNA damage is caused by intrinsic factors associated with
cellular metabolism, such as reactive oxygen species and hydrogen peroxide,
and extrinsic factors, such as ionizing radiation, UV radiation, and
chemotherapeutic agents including reactive chemicals, topoisomerase poisons,
and hydroxyurea (HU) which depletes nucleotide pools (1,2). Cells are
particularly vulnerable to DNA damage during DNA replication because many
DNA lesions cause replication forks to stall. Cellular responses to replication
stress are extremely important in cancer therapy, as a number of
chemotherapeutic drugs target DNA metabolism and cause replication stress,
including topoisomerase poisons and HU. Cells respond to stalled forks in
several ways. Single-stranded DNA (ssDNA) bound by RPA accumulates at
stalled forks and is a major signal for downstream events including fork repair
and checkpoint activation. The replisome at stalled forks is stabilized by
proteins that function in DNA repair and the DNA damage checkpoint response,
including RPA, ATR-ATRIP, ATM, BLM, and INO80 (3-6); the action of these
proteins may preserve the fork structure while the damage is repaired, allowing
replication to resume. Alternatively, error-prone translesion synthesis (TLS)
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polymerases may be recruited to monoubiquitinated proliferating cell nuclear
antigen (PCNA), allowing lesion bypass in a damage tolerance pathway (7,8).
Type I and type II topoisomerases play key roles in normal DNA replication.
Topoisomerase I (type I) is thought to play a major role in relaxing positive
supercoils produced in front of replication forks during duplex DNA unwinding by
the replicative helicase . Topoisomerase IIα (TopoIIα), a type II enzyme, has
roles in chromosome condensation and decatenation, is also present in the
replisome, and is proposed to relax positive supercoils ahead of replication forks
(9-11). Although it is known that topoisomerase poisons cause replication
stress, specific roles for topoisomerases in response to replication stress have
not been defined.
If stalled forks are not restarted in a timely manner, they may be
converted to unusual DNA structures and collapse creating a one-ended doublestrand break or “double-strand end” (DSE). Certain types of damage, such as
single-strand breaks, may cause direct fork collapse to DSEs. As with doublestrand breaks, the checkpoint kinases ATM and ATR are recruited to DSEs and
activated, leading to histone H2AX phosphorylation (γ-H2AX) in the vicinity of
DSEs (12). This chromatin modification is important for fork repair and
checkpoint activation, and once collapsed forks are repaired, γ-H2AX is replaced
by unmodified H2AX (13-15). Homologous recombination (HR), involving
RAD51-mediated strand invasion, plays a major role in restarting stalled and
collapsed forks (5). NHEJ factors also play a role in cell survival after replication
stress (16).
Replication stress activates the intra-S checkpoint (5). ssDNA-RPA at
stalled forks is bound by ATRIP leading to activation of its obligate binding
partner ATR. ATR activation depends on RAD17 (plus Rfc2-5) loading of the
RAD9-HUS1-RAD1 complex (9-1-1; a scaffold and processivity factor structurally
related to PCNA) through a RAD9-RPA interaction. RAD9 recruits TopBP1, an
essential factor for ATR activation. ATR phosphorylates RAD17, which recruits
Claspin to be phosphorylated by ATR, and phosphorylated RAD17-Claspin
promotes ATR phosphorylation/activation of Chk1 kinase, which phosphorylates
proteins that stabilize the stalled fork and prevent late origin firing.
Metnase is a human protein that interacts with DNA ligase IV,
topoisomerase IIα (TopoIIα), Pso4, and NBS1, and promotes NHEJ, DNA
integration, and TopoIIα-dependent chromosome decatenation (17-20).
Metnase has SET (protein methylase) and nuclease domains. It methylates
histone H3 at lysines 4 and 36, which are associated with “open” chromatin and
may increase accessibility of repair factors to damaged DNA. Metnase
knockdown confers mild sensitivity to ionizing radiation (17). Because Metnase
functions in NHEJ and regulates TopoIIα activity, we investigated whether it
plays a role in replication or replication fork restart after stress. We show here
that Metnase promotes cell proliferation, and cell survival after replication stress
caused by HU, the topoisomerase I poison camptothecin (CPT), and UV-B.
Metnase does not influence replication fork progression, but it strongly
influences restart of stalled forks. Additionally, it co-immunoprecipates with
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PCNA and RAD9. We further show that Metnase promotes resolution of HUinduced γ-H2AX foci, enhances TopoIIα-dependent relaxation of positively
supercoiled DNA, and co-immunoprecipitates with PCNA and RAD9. These
results establish Metnase as a key regulatory factor in the human replication
stress response.
MATERIALS AND METHODS
Cell lines, RNAi-suppression of Metnase, and expression of V5-tagged
Metnase
Cell lines were cultured in D-MEM with 10% (v/v) fetal bovine serum
supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin, or 1×
antimycotic/antibiotic (Invitrogen, Carlsbad, CA), respectively. Metnase was
overexpressed in HEK-293 and HEK-293T cells as described (19). V5-tagged
Metnase expression was confirmed by Western blot with a monoclonal antibody
against the V5 tag (Invitrogen). Metnase was downregulated by transfecting
cells with a pRNA/U6-Metnase RNAi vector and selecting in growth medium with
150-200 µg/ml hygromycin B (Sigma-Aldrich, St. Louis, MO), or with an Metnase
shRNA vector (pRS-shMetnase). Control cells were transfected with empty
pRNA/U6 or pRS-shGFP vectors. Metnase expression was measured by RTPCR and by Western blots using antibodies to native Metnase as described
(17).
Cell proliferation and replication stress sensitivity assays
Cell proliferation was analyzed in triplicate in treated or mock-treated
populations incubated in fully supplemented media at 37°C, 5% CO 2 , and at
indicated times cells were harvested and counted with a Coulter counter. Cell
sensitivity to CPT and HU was determined by seeding 1000 cells per 10 cm
(diameter) dish in drug-free medium (to determine plating efficiency, PE), and
100,000 cells per dish in medium with CPT or HU, incubating for indicated times,
then cells were rinsed with PBS, fresh growth medium was added, and cells
were incubated for 12-14 days before colonies were stained with 0.1% crystal
violet in methanol and counted. For UV sensitivity, cells were seeded and
incubated for 24 h as above, rinsed with PBS, exposed to UVB in a biological
safety cabinet equipped with a Phillips UVB fluorescent bulb, then fresh growth
medium was added and cells were incubated and colonies scored. UV doses
were determined by using a UVX dosimeter (UVP, Upland, CA). PE was
calculated as the number of colonies divided by the number of cells plated
without drug or UVB treatment. Percent survival was calculated as the number
of colonies formed with drug or UVB treatment divided by the number of cells
plated times the PE.
Cell cycle distributions and cell death
Cell cycle distributions were measured by fixing cells with 70% ethanol and
staining with 0.2 mg/ml propidium iodide in a fresh solution containing 1% (v/v)
Triton X-100 and 2 U of DNAse-free RNAse (all from Sigma-Aldrich) for 15 min
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at 37°C or 30 min at room temperature. Samples were analyzed using a
FACScan or a FACScalibur flow cytometer (Becton Dickinson, Franklin Lakes,
NJ). The percentages of cells in G1, S, or G2/M phases were calculated by
dividing the number of cells in each cell cycle stage by the total number of PI
positive cells after normalizing to controls that were not stained with PI and
converting values to percentages. Apoptosis and cell death were analyzed by
flow-cytometric measurement of annexin-V expression and propidium iodide
incorporation by using the Annexin V-FITC Apoptosis Detection Kit I (BD
Pharmingen, San Diego, CA). All flow cytometry data were analyzed with
FlowJo software (Ashland, OR, http://www.flowjo.com/).
DNA replication by BrdU incorporation and DNA fiber analysis
Log phase cells, or cells treated with 5 mM HU for 18 h were washed with PBS
and released into fully supplemented D-MEM containing 10 μM BrdU. Aliquots
were removed at indicated times, cells were fixed, permeabilized, and stained
using the FITC BrdU Flow Kit (BD Pharmingen), and analyzed by flow cytometry
as above. DNA fibers were analyzed as described (21). Briefly, cells were
grown in six-well tissue culture dishes, 20 μM IdU was added to growth medium,
mixed and incubated for 10 min at 37°C. Media was removed and cells were
washed with PBS, followed by a 100 μM thymidine wash. Then, cells were
either treated with HU or mock treated, medium was replaced with fresh medium
containing 20 μM CldU and cells were incubated for 20 min at 37°C. Cells were
harvested, resuspended in PBS, 2500 cells were transferred to a positively
charged microscope slide (Superfrost/Plus, Daigger, Vernon Hills, IL), lysed with
6 μl of 0.5% SDS, 200 mM Tri-HCl, pH 7.4, 50 mM EDTA, and incubated at room
temperature for ~5 min. Slides were tilted to allow DNA to spread via gravity,
covered with aluminum foil, air-dried for 8 min, fixed for 5 min with 3:1
methanol:acetic acid (prepared fresh), air dried for 8 min, and stored in 70%
ethanol at 4°C overnight. Slides were deproteinized in 2.5 N HCl at 37°C for 1
h, blocked with 5% BSA and labeled sequentially for 1 h each with mouse antiBrdU antibody (BD Biosciences, San Jose, CA), secondary goat anti-mouse
Alexa-568 (Invitrogen), rat anti-BrdU (Accurate Chemical, Westbury, NY), and
secondary donkey anti-rat Alexa-488 (Invitrogen). Slides were mounted in
PermaFluor aqueous, self-sealing mounting medium (Thermoscientific,
Waltham, MA). DNA fibers were visualized using an LSM 510 confocal
microscope (Zeiss, Thornwood, NY) optimized for each Alexa dye. Images were
analyzed using Zeiss LSM Image Browser software.
Analysis of γ-H2AX positive cells
Cells were treated with 10 mM HU for 18 h in fully supplemented D-MEM,
released into fully supplemented D-MEM for indicated times, harvested,
cytospun, and fixed as described previously (22). Cells were re-hydrated in PBS
for 5 min at room temperature and blocked with 2% BSA in PBS for 30 min.
Primary staining was done with γ-H2AX monoclonal mouse antibody (Merck,
Nottingham, UK) incubated at 4˚C overnight. Cells were washed 3 times in TBS156

T for 5 min at room temperature. Secondary staining was accomplished with an
Alexa488-tagged goat anti-mouse antibody (Invitrogen) for 1 h at room
temperature. The cells were washed 3 times in TBS-T for 5 min at room
temperature, then covered in Vectashield mounting media with DAPI (Vector
Laboratories, Burlingame, CA) and sealed. Images were obtained with a
Radiance 2100 inverted confocal microscope (BioRad, Hercules, CA) fitted with
filter sets specific for DAPI and FITC/Alexa488. Images were optimized
consistently with the ImageJ program (http://rsb.info.nih.gov/ij/).
Protein immunoprecipitation
Protein samples were pre-treated with 4 U of DNaseI, incubated at 37°C
for 10 min, immunoprecipitated using 0.5-5 mg of protein and antibodies to V5,
PCNA (Abcam, Cambridge, MA), RAD9 (Abcam), or TopoIIα (TopoGEN, Port
Orange, FL), samples were incubated overnight at 4°C, then 25 μl of A/G (1:1)
agarose beads (Invitrogen) were added and incubated for 1 h at 4°C, centrifuged
at 300 × g for 2 min at 4°C. Supernatants were removed and beads were
washed four times with M-PER buffer (Thermoscientific). Beads were
centrifuged at 300 × g for 2 min at 4°C, boiled for 10 min, and centrifuged at 300
× g for 2 min at 4°C. The supernatants were transferred to new tubes, samples
were boiled for 10 min, separated by SDS-PAGE, and analyzed by Western
blotting.
Relaxation of positive supercoiled DNA
Positively supercoiled DNA was prepared as described (9). Positive
supercoil relaxation reactions were performed in a total volume of 20 μl in 10 mM
Tris-HCl, pH 7.9, 175 mM KCl, 0.1 mM EDTA, 5 mM MgCl 2 , 2.5% glycerol, 0.5
mM ATP (USB Co., Cleveland, OH), 2 U TopoIIα, 180 ng Metnase (when noted),
and 0.3 μg DNA. Aliquots were removed at indicated times and reactions were
stopped with 4 μl of 0.77% SDS, 77 mM EDTA. Products were separated on 1%
agarose gels and densitometry was performed using Image J software.
Background values were subtracted from signals, resulting values were
normalized to signals at initial time points, and plotted as function of time in two
independent experiments.
RESULTS
Metnase promotes cell proliferation
Metnase is expressed in a wide variety of human tissues (17) and in all human
cell lines tested, except those transformed by T-antigen such as HEK-293T cells
(unpublished results). Overexpression of Metnase in HEK-293T increases cell
proliferation (19). HEK-293 cells express Metnase, but not T-antigen, and stable
shRNA knockdown of Metnase in HEK-293 cells significantly reduced cell
proliferation rate compared to control cells (Figure 1A). We have shown
previously and confirmed in this study that Metnase overexpression in HEK293T increases cell proliferation (Figure 1B). Moreover, cells stably transfected
with Metnase shRNA vectors either cease to proliferate after 2-3 months or
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revert to normal. These results indicate that Metnase promotes proliferation of
human cells, and suggest that Metnase is very important for growth of human
cells that do not express T antigen.
Metnase promotes cell survival and DNA replication after replication stress
The effect of Metnase on cell proliferation, coupled with its DNA repair
properties and functional interaction with TopoIIα (17,19), suggested that
Metnase may have a role in replication and/or rescuing cells from replication
stress at sites of spontaneous DNA damage. We therefore tested whether
Metnase regulates sensitivity to replication stress induced by HU, CPT, and UVB (Figure 2A). Metnase knockdown sensitized HT1080 cells to 1 mM HU by
more than 1000-fold (P = 0.01), and to 0.2-0.5 µM CPT by nearly 10-fold (P ≤
0.011) (all statistical analyses in this study were performed by using t tests).
Metnase knockdown sensitized HEK-293 cells to a UV-B dose of 11.2 J/m2 by
nearly 20-fold (P = 0.007). When cultured in a low concentration of HU (0.1
mM), HEK-293 cells proliferated at a slow rate, but Metnase knockdown cells
showed almost no proliferative capacity; this effect specifically reflects the
Metnase defect since Metnase overexpression in HEK-293T significantly
enhanced proliferation under these conditions (Figure 2B). The hypersensitivity
of Metnase knockdown cells to replication stress reflects, at least in part,
enhanced cell death via apoptosis, as shown by the nearly 30-fold increase in
the apoptosis marker annexin V, and >6-fold increase in inviable cells (unable to
exclude propidium iodide) (both P < 0.005). The marked sensitivity of Metnase
knockdown cells to replication stress contrasts with their mild sensitivity to
ionizing radiation (17).
To investigate the mechanism by which Metnase promotes cell
proliferation and resistance to replication stress, we tested whether Metnase
expression level influenced DNA replication by measuring BrdU incorporation
and cell cycle distributions by flow cytometry, in unstressed cells and after
release from replication stress. In log phase (untreated) HEK-293 cells,
Metnase knockdown had no effect on BrdU incorporation during a 30 min
incubation (Figure 3A). However, when cells were pretreated with 5 mM HU for
18 h and then released into BrdU, Metnase knockdown in HEK-293 significantly
reduced BrdU incorporation (~2-fold), and Metnase overexpression in HEK-293T
significantly increased BrdU incorporation (Figure 3B, C). Although neither
over- nor underexpression of Metnase significantly affected cell cycle
distributions of unstressed cells (Supplemental Figure S1A), when treated with 5
mM HU for 18 h and released, HEK-293T cells overexpressing Metnase entered
S-phase more rapidly than control cells (seen 1 h after release from HU), and
entered G2 phase more rapidly (seen 7 h after release from HU (Supplemental
Figure S1B). Somewhat stronger effects were seen when Metnase was
overexpressed in HEK-293 cells (Supplemental Figure S1C); this may reflect the
fact that HEK-293T cells show robust proliferation even though they do not
express Metnase. When HEK-293 Metnase knockdown cells were treated with 5
mM HU for 18 h and released, the opposite effect was seen. In two independent
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knockdown cell lines, there were marked accumulations of S phase cells 10 and
18 h after release from HU (Supplemental Figure S1D), indicating that Metnase
knockdown prolongs S phase after replication stress. These results support the
idea that Metnase promotes DNA replication in cells recovering from replication
stress.
Metnase promotes replication fork restart
To gain a better understanding of the role of Metnase in replication and the
replication stress response, we analyzed replication fork restart, new origin
firing, and replication speed by using DNA fiber analysis. Log phase HEK-293
cells stably transfected with vectors expressing shRNA targeting Metnase, or
GFP as control, were labeled with IdU for 10 min, then incubated with or without
5 mM HU for one h, briefly washed with thymidine and then incubated with CldU
for 20 min. Cells were lysed on glass slides and DNA fibers were stretched by
gravity, fixed, IdU was stained red and CldU was stained green, and DNA fibers
were quantified using confocal-microscopy (Figure 4A, B). In untreated control
cells, ~90% of fibers showed adjacent red-green signals indicative of continuing
forks, and ~10% had only green signals indicating forks that initiated after IdU
was removed (“new forks”). When control cells were treated with HU, continuing
forks (those that stalled and restarted) were moderately reduced to ~65% (P =
0.0014), new forks that initiated after HU treatment showed a slight but not
statistically significant increase to ~20%, and ~15% of forks stopped and failed
to restart. The pattern observed with untreated Metnase knockdown cells was
similar to untreated wild-type cells, with predominantly continuing forks and a
small percentage of new forks. Strikingly, when Metnase knockdown cells were
treated with HU, the percentage of stopped forks greatly increased (to ~90%)
and there was a corresponding large decrease in the percentage of continuing
forks (both P ≤ 0.0008). New forks were extremely rare in HU treated Metnase
knockdown cells, however new forks are also rare in untreated cells, and the
decrease with HU treatment was not statistically significant (P = 0.3). These
results provide direct evidence that Metnase plays a critical role in restarting
stalled replication forks, and further suggest that Metnase may regulate new
origin firing when cells experience replication stress.
To determine whether Metnase regulates the speed of replication, we
measured average fiber lengths. As expected, red fibers were shorter than
green since cells were treated with IdU (red) for 10 min and CldU (green) for 20
min. Fibers were longer in unstressed cells than after HU treatment (Figure 4C).
However, Metnase had no effect on fiber lengths in either HU treated or
untreated cultures. We conclude that Metnase regulates the efficiency of
replication fork restart, and possibly initiation after replication stress, but it has
no effect on the speed of ongoing forks.
Metnase promotes resolution of γ-H2AX induced by replication stress
Replication stress causes fork collapse to DSEs marked by phosphorylation of
histone H2AX to γ-H2AX. Elimination of the γ-H2AX signal over time reflects
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DSE/fork repair. Metnase and classical NHEJ proteins promote survival after
replication stress and influence replication fork restart (21,23-25) (this study),
and Metnase promotes NHEJ and interacts with the key NHEJ protein DNA LigIV
(17,18). We therefore tested whether Metnase influences resolution of HUinduced γ-H2AX by treating cells with 10 mM HU for 18 h, then releasing into
normal growth medium and examining γ-H2AX by immunofluorescence
microscopy. Because HEK-293 and HEK-293T cells used in these experiments
adhere poorly, cells were cytospun prior to fixation and immunocytochemical
staining. For this reason, individual γ-H2AX foci are not always detectable.
Instead γ-H2AX signals typically appears as diffuse nuclear staining and cells
were scored as either γ-H2AX positive or negative (representative images are
shown in Figure 5A). Consistent with the enhanced sensitivity of Metnase
knockdown cells to HU, γ-H2AX persisted longer in the knockdown cells, with
significant differences from controls at both 6 and 24 h after release from HU
(Figure 5B, P < 0.0001). Similarly, overexpression of Metnase in HEK-293T
cells accelerated the resolution of γ-H2AX signals (Figure 5C (P ≤ 0.0055). Note
that in all four cell lines, similar percentages of cells were γ-H2AX positive at the
end of the 18 h HU treatment. These results indicate that Metnase promotes
resolution of γ-H2AX after cells are released from replication stress, but Metnase
does not prevent fork collapse to DSEs over the course of this relatively long HU
treatment.
Metnase co-immunoprecipitates with PCNA and RAD9
Because Metnase is involved in the replication stress response, we explored its
interactions with proteins at the replication fork. PCNA is a key scaffold protein
that mediates binding of numerous proteins in the replisome and promotes
replication processivity (7). Metnase co-immunoprecipitated with PCNA, and
vice versa, in unstressed cells and after treatment with HU (Figure 6A). PCNAinteracting proteins share a conserved binding motif, the PIP box. Metnase has
a highly conserved PIP box (Supplemental Table S1) suggesting it directly
interacts with PCNA. Interestingly, Metnase also co-immunoprecipitated with
RAD9, a member of the 9-1-1 complex that is structurally and functionally related
to PCNA, and that is recruited to stalled and/or collapsed replication forks
(Figure 6B). Although this interaction appeared stronger when RAD9 was
immunoprecipitated from HU treated cells, a similar enhancement was not seen
with HU treatment when Metnase was immunoprecipitated. Metnase did not coimmunoprecipitate with the 32 kDa subunit of RPA (Figure 6C), indicating that
Metnase is present within the replisome, but is not closely associated with
ssDNA at stalled forks. These results indicate that Metnase is closely
associated with replication stress factors that control TLS, fork processing via
HR mechanisms, and checkpoint signaling.
Metnase interacts with TopoIIα and promotes TopoIIα-dependent relaxation
of positively supercoiled plasmid DNA
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Metnase interacts with TopoIIα and promotes TopoIIα-dependent chromosome
decatenation (19). TopoIIα is present in the replisome (11) and has been
implicated in DNA replication through relaxation of positive supercoils that
accumulate ahead of replication forks (9). We found that Metnase significantly
enhanced TopoIIα-dependent relaxation of positive supercoils during a 5 min
time course, but Metnase was not required to achieve full relaxation within an
hour (Figure 7A, B). To gain insight into whether Metnase functions in the
replication stress response through its interaction with TopoIIα, we tested
whether the interaction between Metnase and TopoIIα was affected by
replication stress. HEK-293 cells were treated with 5 mM HU for 3 h, and cell
extracts were prepared and analyzed by co-immunoprecipitation of Metnase and
TopoIIα. As shown in Figure 7C, Metnase and TopoIIα show a robust
interaction regardless of which protein was immunoprecipitated, but this
interaction was not affected by HU treatment. These results suggest that
Metnase interaction with TopoIIα may promote TopoIIα processing of DNA
structures in front of replication forks.
DISCUSSION
Although Metnase appeared very late in evolution, in anthropoid primates (26), it
influences several important aspects of DNA metabolism including NHEJ, DNA
integration, and chromosome decatenation (17-20). Through interaction with
TopoIIα, it regulates cellular resistance to common chemotherapeutics (22,27).
The present study establishes another important role for Metnase in the
replication stress response. Given how late Metnase appeared in evolution, it is
not surprising that it does not influence replication fork progression. Instead,
Metnase functions during replication stress since Metnase affected BrdU
incorporation, S phase progression, and fork restart by DNA fiber analysis only
when cells were subjected to replication stress (Figures 3, 4, S1). Metnase
knockdown conferred a marked defect in fork restart during a 20 min period after
a brief (1 h) HU treatment (Figure 4). This result indicates that Metnase plays a
key role in restarting stalled forks, because the brief HU treatment will cause
mainly fork stalling. Also, when forks collapse, restart is largely dependent on
HR, an inherently slow process that involves RAD51 replacement of RPA on
ssDNA, and strand invasion of sister chromatids by RAD51 filaments (5).
However, when cells were subjected to longer periods of replication stress,
Metnase promoted resolution of γ-H2AX (Figure 5), which marks collapsed forks.
This indicates that Metnase also promotes restart of collapsed forks. Another
late-evolving protein that functions in replication fork restart is PARP-1. PARP-1
is not found in yeast, but is present in higher eukaryotes. PARP-1 recruits the
ancient DNA repair endonuclease MRE11 to stalled forks, which is proposed to
process structures at stalled forks, leading to RPA recruitment and eventual
restart via HR (28).
Metnase might promote replication fork restart in a variety of ways, as
illustrated in Figure 8. Metnase promotes NHEJ (17) and other factors involved
in NHEJ are known to promote cell survival after replication stress (16,24).
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NHEJ factors might promote rejoining of DSEs at collapsed forks, but it seems
that this type of repair would be highly inaccurate (and genome destabilizing)
since each collapsed fork produces only a single broken end. It is possible that
NHEJ factors promote fork restart indirectly through interactions with HR factors
(29). When replication forks stall, the initial cellular response is to stabilize the
replisome to prevent fork collapse. Metnase does not appear to play a role in
fork stabilization over an extended period of replication stress, because altering
Metnase levels had no effect on the percentage of cells with collapsed forks (γH2AX positive) after an 18 h HU treatment (Figure 5). Although it is clear that
Metnase promotes resolution of γ-H2AX signals, further studies are required to
determine whether this reflects enhanced repair of collapsed forks via NHEJ or
other mechanisms.
Metnase could promote fork restart through its interactions with the
replisome factors PCNA and RAD9. Although it is not yet known whether
Metnase interacts directly with these proteins, the fact that the Metnase SET
domain has a conserved PIP box is highly suggestive that Metnase interacts
directly with these proteins. Regardless, our results clearly place Metnase in the
vicinity of stalled replication forks. The Metnase SET domain encodes a protein
methylase, and Metnase is known to methylate histone H3 and itself (17,19).
Metnase could regulate PCNA and/or RAD9 function by methylating these
proteins. PCNA regulates TLS through direct interactions with TLS polymerases
(7), thus Metnase may enhance fork restart after UV by enhancing TLS at UV
lesions.
RAD9 has well-established roles in the intra-S checkpoint response (5).
Metnase could promote fork restart by influencing checkpoint activation or
downstream checkpoint-dependent processes such as inhibition of origin firing.
We are currently investigating the effects of Metnase on checkpoint factors
downstream of RAD9, including Chk1. Metnase is not required for the p53/Chk2
arm of the DNA damage checkpoint response since replication stress-induced
cell death in Metnase knockdown cells shows a robust apoptotic response
(Figure 2C). Metnase may have a more general role in fork restart through
chromatin modification in the vicinity of stalled and collapsed forks. It is
noteworthy that Metnase methylates histone H3 lysines 4 and 36, which are
specifically associated with “open” chromatin (17). Thus, Metnase could
promote fork restart by enhancing access of repair factors to stalled and
collapsed forks.
Finally, Metnase could influence fork restart through its direct interaction
with TopoIIα, another factor within the mammalian replisome (11). TopoIIα is
proposed to relax positive supercoils that form ahead of replication forks (9).
When replication forks stall, the MCM helicase complex can continue to unwind
duplex DNA, uncoupled from the replicative polymerases, producing excess
ssDNA that is bound by RPA and triggering the intra-S checkpoint (5,30).
Continued DNA unwinding by MCM will also increase positive supercoiling that
may drive unusual DNA structures at stalled forks (30). By enhancing TopoIIαdependent relaxation of positive supercoils, Metnase could promote a favorable
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topological state that results in timely fork restart, particularly when unusual
structures form, such as “chicken feet,” since the resolution of such structures is
probably dependent on the topology of the stalled fork. Local topology could
also influence restart of collapsed forks since HR-mediated invasion of broken
ends into sister chromatids requires unwinding of the sister duplex. Note that
the models described above are not mutually exclusive: Metnase may have
different roles depending on the specific structures at stalled or collapsed
replication forks.
Prior studies have established that Metnase is highly expressed in
actively proliferating tissues (17). We have recently shown that Metnase is
frequently overexpressed in leukemia and breast cancer cell lines, and
importantly, downregulating Metnase greatly enhances tumor cell sensitivity to
common chemotherapeutics including epididophylotoxins and anthracyclines
(22,27). The current study establishes Metnase as a critical factor in the
replication stress response. Metnase is therefore an excellent target for
therapeutic strategies that block DNA synthesis, or that exploit defects of tumor
cells in replication fork restart (31,32), and it may prove to be an important target
in the treatment of a wide variety of tumor types.
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Figure Legends
Figure 1. Metnase promotes cell proliferation. A) Cell growth was monitored in
HEK-293 cells transfected with shGFP (control) or shMetnase vectors. B) Cell
growth was monitored in HEK-293-T cells, which do not normally express
Metnase, transfected with the pCAPP-Metnase expression vector or empty
pCAPP. Plotted are averages (±SD) of 2-3 determinations per time-point. *
indicates P<0.05, ** indicates P<0.01. Metnase expression is shown in
representative Western blots with β-actin loading control (insets).
Figure 2. Metnase promotes cell survival after DNA replication stress. A)
Average percent cell survival (± SD) after HU, CPT, or UV-B treatments
measured as relative plating efficiency for HT1080 or HEK-293 cells stably
transfected with control or shRNA-Metnase vectors. Data are from 2-3
independent experiments per condition; * indicates P = 0.0127, ** indicates P ≤
0.01. B) Average growth rates (±SD) of control HEK-293 and sh-Metnase
knockdown cells, and control HEK-293T or Metnase overexpression cells in
medium containing 0.1 mM HU; data are from 2-3 independent experiments per
cell line. C) HEK-293 control or Metnase knockdown cells were treated with 5
mM HU for 6 h and the percentages of cells expressing annexin V or
incorporating propidium iodide were determined by flow cytometry. Values are
averages (±SD) from 3 independent experiments.
Figure 3. Metnase promotes DNA replication after release from replication
stress. A) Log phase HEK-293 cells expressing normal or low levels of Metnase
were incubated with 10 µM BrdU for 30 min and average percentages (±SD) of
BrdU+ cells are shown for two determinations per strain. B) HEK-293 control and
Metnase knockdown cells were treated with 5 mM HU for 3 h and released into
medium with 10 µM BrdU. Average fold increases (±SD) in the percentage of
+
BrdU cells relative to untreated cells (no HU, no BrdU) are plotted for 3
independent experiments per cell line. * indicates P = 0.042, ** indicates P =
0.0047. C) BrdU incorporation after HU release from HEK-293T control and
Metnase overexpression cells as in panel B, except cells were treated with HU
for 18 h; * indicates P ≤ 0.03.
Figure 4. Metnase promotes replication fork restart. A) IdU and CldU labeling
scheme is shown above representative confocal microscope images of DNA
fibers, with IdU stained red and CldU stained green. B) Quantification of fiber
types. At least 150 fibers were scored per treatment, per cell line for each of
three experiments; ** indicates P ≤ 0.0014. C) Fiber lengths were measured by
using LSM 510 Image Browser software. Plotted are averages (±SD) of triplicate
experiments in which 150-500 fibers were scored per treatment, per experiment.
nd, none detected.
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Figure 5. Metnase promotes resolution of replication stress-induced γ-H2AX.
A) Representative confocal microscope images of HEK-293 and HEK-293T cells
over- or under-expressing Metnase were treated with 10 mM HU for 18 h and
released into growth medium for 24 h. Aliquots of cells were removed at
indicated times, cytospun, stained with DAPI (blue) and antibodies to γH2AX
(green) and imaged by confocal microscopy. B) Percentage of γ-H2AX positive
cells among total DAPI stained cells. An average of >190 cells were counted
per slide, 10 slides per experiment. Values are averages (±SD); ** indicates P ≤
0.0055.
Figure 6. Metnase interacts with PCNA and RAD9, but not RPA32. A)
Reciprocal co-immunoprecipitation of V5-tagged Metnase and native PCNA from
cells treated with 5 mM HU for 18 h, tested immediately or 30 min after release
from HU, or untreated. Input represents 0.5% of immunoprecipitation. Results
are representative of at least three independent experiments. B, C) Reciprocal
co-immunoprecipitation of V5-tagged Metnase with native RAD9 and native RPA
as in panel A, except HU treated cells were only tested immediately after
treatment.
Figure 7. Metnase interacts with TopoIIα and stimulates relaxation of positive
supercoils. A) Predominantly positively-supercoiled plasmid DNA samples were
treated with TopoIIα (2 U) with or without Metnase (180 ng) for indicated times,
and topological forms were detected on ethidium bromide stained agarose gels.
B) Gel images were scanned and the percentage of positively-supercoiled DNA
remaining at each time point was quantitated. Values are averages (±SD) of two
determinations per condition, normalized to 100% at t=0; ** indicates P = 0.007.
C) Co-immunoprecipitation of V5-tagged Metnase and native TopoIIα; data
presented as in Figure 6B.
Figure 8. Potential roles of Metnase in the replication stress response. See text
for details.
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Supplemental information
Figure S1

Figure S1. Metnase promotes cell cycle progression after replication stress. A)
Cell cycle distributions of log phase cultures of HEK-293T, HEK-293 cells stably
transfected with empty or Metnase overexpression vectors, and HEK-293 cells
stably transfected with empty or Metnase knockdown vectors. Values in left
graph are averages (±SD) from three experiments; other graphs show data from
single experiments. B, C) Cell cycle distributions of HEK-293T or HEK-293
cells, with or with Metnase overexpression, after 18 h treatment with 5 mM HU
and release into normal growth medium for indicated times. Values are
averages (±SD) of three experiments; * indicates P < 0.05, ** indicates P < 0.01.
D) Cell cycle distributions of HEK-293 cells, with or without Metnase knockdown
following HU release. Data presented as in panels B and C.
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Table S1. Conserved PIP boxes in Metnase and other human DNA
repair/metabolism proteins.
Protein
Metnase
PARP-1
DNMT1
DNA Polβ
p66
MYH
UNG2
APE2
XPB
BLM
RECQL5β
p15 PAF
ING1b
MDM2
WSTF

Function(s)
NHEJ, decatenation,
fork restart
DNA repair, fork
restart
DNA
methyltransferase
DNA repair
polymerase
DNA polδ subunit
BER glycosylase
BER glycosylase
BER endonuclease
NER endonuclease
DNA repair helicase
DNA repair helicase
Cell growth
promotion
Apoptosis
E3 ubiquitin ligase
Chromatin
remodeling

PIP box*
(119) VVQKGLQ-FH

Reference
(1)

(668) PVQDLIKMIF

(2)

(162) TRQTTITSHF

(3)

(215) VEQLQKV-HF

(4)

(454)
(521)
(2)
(288)
(988)
(81)
(962)
(60)

(5)
(6)
(7)
(8)
(9)
(10)
(10)
(11)

NRQVSITGFF
MGQQVLDNFF
IGQKTLYSFF
RGQKNLKSYF
QTQLRIDSFF
TNQQRVKDFF
EAQN-LIRHF
KWQKGIGEFF

(7)
GEQLHLVNY
(481) PIQMIVLTYF
(662) LLQDEIAEDY
(1024)RYQDIIHSIH
(1099)ALQASVIKKF
(1432)TEQCLVALLH
[K-A]QxxConsensus PIP
I/L/Vxx(F/Y/H/W)
2
box:

(12)
(13)
(14)

(15)

*All proteins have the core PIP Q-I/L/V motif, and nearly all (including Metnase)
have the C-terminal pair of F/Y/H residues (shown in red). Many PIP boxes
have upstream K and/or A residues; Metnase, and PARP-1 have conservative
substitutions (V for A) at this position, indicated in green.
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6.7. New Techniques Developed for the Laboratory
Adenovirus expressing ISce-I used for HR assays and Chromatin
Immunoprecipitation
The adenovirus expressing ISce-I was a kind gift from Kristoffer Valerie
[152]. The virus was propagated in AD293 cells (Stratagene, La Jolla, CA) using
a method adapted from previously described protocols [152-154].
Note: All media used when handling the virus should is warmed to room
temperature.
Reagents:
Virus Storage Buffer (2x):
20 mM Tris-HCl pH 8.0
4 mM MgCl 2 (FW 203.3)
10% Sucrose
Dilute in PBS
2x Adenovirus Storage buffer:
20 mM Tris-HCl pH 8.0
4 mM MgCl 2

Lysis Buffer:
0.1% SDS
10 mM Tris-HCl pH 7.4
1 mM EDTA
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Adenovirus Propagation
1. Grow Ad293 cells to ~50% confluence in 20 cm tissue culture dishes
(according to manufacturer’s instructions). Wash cells with PBS once.
2. Add 5 mL of OptiMEM to cells.
3. Mix virus in 1 mL OptiMEM per plate (10 viruses per cell).
4. Add the virus mixture to the cells and swirl to mix.
5. Incubate at 37°C for 2 h.
6. Add 10 mL of 10% DMEM (do not use antimycotic as this will cause cell
death, do not remove virus from the media).
7. Incubate for 3-5 days (usually after 4 days cells will start floating, when >80%
of cells are floating virus can be harvested).

Note: It is very important that the space between cells and virus be reduced to a
minimum to ensure efficient contact (through diffusion) between virus particles
and cells, so adjust the volume of growth medium according to the dimensions of
the dish you are using.

Harvesting Viral Particles
1.

Harvest cells (remove cells that are attached by flushing with media).

2.

Collect cells in a 250 mL bottle (sterilized).

3.

Spin at 8000 rpm (7169 x g) for 10 min at 4°C and remove supernatant.

4.

Resuspend cell pellet in 8 mL PBS and transfer to a 50 mL conical tube.
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5.

Freeze at -80°C.

6.

Thaw at 37°C and immediately vortex for 30 sec.

7.

Freeze in methanol/dry ice bath.

8.

Repeat steps 5-6 four times.

9.

Centrifuge at 3000 rpm (1000 x g) for 30 min at 4°C.

10.

Transfer 8 mL of supernatant to a new tube and add 4.4 g of CsCl.

11.

Weigh 1 mL of CsCl mixture (it should be ~1.35 g/mL)

12.

Adjust density to be 1.35 g/mL by adding CsCl.

13.

Centrifuge at 32,000 rpm (22937 x g) at 10°C for 22 h.

14.

Remove the viral particle band with 18G needle.

15.

Add equal volume of 2x viral storage buffer.

16.

Aliquot in a small volume (10 μL) and store at -80°C.

Determination of virus concentration by OD 260 reading:
Conversion factor: 1.1 x 1012 viral particles/OD 260 . Quantification was done using
the protocol outlined in AdEasy vector system manual by Quantum
Biotechnologies (Qbiogene, Carlsbad, CA). This protocol routinely produces
virus titers of 3 x 109 viral particles/μL.
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Adenovirus Infection for Creating an ISce-I DSB
In order to use the Ad-ISce-I to create a DSB, one must use cells that have an
engineered ISce-I site already, for example HT256 cells, or HT1080-1904 (see
Appendix for more details and references).
1.

Wash cells with PBS once.

2.

Add 5 mL of OptiMEM to cells. It is very important that the space between
cells and floating virus be reduced to a minimum to ensure efficient
contact (through diffusion) between virus particles and cells. Therefore,
adjust the volume of media according to the dimensions of the dish you
are using (i.e., use 1 ml of OptiMEM for a 10 cm dish and 5 mL for a 20
cm dish).

3.

Mix virus in an appropriate volume of virus dilution buffer to achieve a
multiplicity of infection (MOI) of 100-1000 virus particles per cell.

4.

Add the virus mixture to the cells and swirl to mix.

5.

Incubate at 37°C for 3 h when infecting CHO or HT1080 cells (incubation
times may need to be adjusted to suit specific cell lines).

6.

Remove media and add fresh growth medium to cells. Incubate overnight
to allow cells to recuperate.

7.

Cells are ready for manipulation (i.e. electroporation, drug treatment,
homologous recombination assay, chromatin immunoprecipitation, etc.)

Note: Allow only 1-2 freeze-thaw cycles of the virus stocks. DO NOT store virus
in OptiMEM, store in virus storage buffer.
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Results
Ad ISce-I does not affect plating efficiency of human cells and is a useful
tool for homologous recombination assays
HT1080-1885 cells contain a single ISce-I site within the neomycin gene
and have been engineered to measure HR (described in more detail in [155]).
HT1080-1885 cells were infected with the ISce-I containing adenovirus at 100
and 1000 multiplicity of infection (MOI) for 3 h. After the infection period cells
were counted, plated (500 cells), and allowed to form colonies for 7 days. The
plating efficiency was calculated by dividing the number of colonies formed by
the number of cells plated, and converting it to percentage values. Results in
figure 3-1A show that the plating efficiency did not vary between the no virus
control and the control virus (beta-galactosidase containing adenovirus),
demonstrating that the adenovirus alone does not affect colony formation ability.
The plating efficiency of cells infected with Ad-ISce-I was slightly lower than the
two controls; however, this difference was not statistically significant.
Nonetheless, this difference could indicate that the Ad-ISce-I affects colony
formation ability of cells; however, neither the virus nor single DSB have an
effect on colony formation. We tested whether Ad-ISce-I could be effectively
used for the HR assay, and Figure 3-1B represents an example of results
obtained. Results showed that indeed Ad-ISce-I gives comparable results to
using plasmid ISce-I as compared to HR frequency values obtained using ISce-I
from a plasmid [155-158]. Furthermore, the HR frequency increased as the MOI
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is increased. This is a valuable new tool to use in the HR assay since there is
minimal cell killing compared to other methods such as electroporation or
lipofectamine infection, and it yields similar results in the HR assay. Chinese
Hamster Ovary (CHO 33) cells, engineered to contain the ISce-I site, had similar
results to the 1885 cells (Figure 3-2), and the HR frequency was comparable to
previously obtained values [159]. There were two important differences between
the 1885 cells and the CHO33 cells; however, in the CHO33 cells the plating
efficiency significantly decreased as the viral MOI is increased, and the DSBinduced HR frequency was only detected at an MOI of 1000. The requirement for
a higher MOI with CHO cells is consistent with the fact that CHO cells express
fewer adenovirus receptors than human cells [160].
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Figure 6.7-1. Ad-ISce-I does not affect plating efficiency in human cells
and is a useful tool in HR assays.
(A) Plating efficiency of HT1080-1885. PE was calculated as the
number of colonies formed divided by the number of cells plated, times 100.
(B) HR assay done in HT1080-1885 cells. HR frequencies were determined
by dividing the number of puromycin resistant colonies (reflects HR), divided
by the number of cells plated times the PE. Cells were treated with no virus,
Ad-ISce-I (I+), or Ad-βgal (I-). 100 and 1000 MOI Ad-ISce-I were used.
Values represent averages (±SD) for three independent experiments.
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Figure 6.7-2. Ad-ISce-I does not affect plating efficiency in Chinese
hamster ovary (CHO) cells.
(A) Plating efficiency of CHO-33 cells. PE was calculated as the
number of colonies formed divided by the number of cells plated, times 100.
(B) Homologous recombination assay done in CHO-33 cells. HR frequency
was determined by taking the number of colonies selected, divided by the
number of cells plated times the PE. Cells were treated with no virus, AdISce-I (I+), or Ad-βgal (I-), 100 and 1000 MOI Ad-ISce-I were used,
represent three independent experiments, *p<0.05,***p<0.001 (t-test).
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Ad-ISce-I rapidly induces DSBs into the ISce-I site
In order to test whether the Ad-ISce-I would be an effective tool to use to
detect recruitment of proteins to a DSB site, we first tested its ability to form a cut
at the ISce-I site. We used quantitative PCR (qPCR) to amplify a 200 bp product
using primers homologous to sequences on either side of the ISce-I site. In the
presence of an intact ISce-I site, a qPCR product can be amplified. However,
when the site has been cut, there is no amplification. Therefore, we measured
the disappearance of the qPCR product and interpreted it as “cutting” at the
ISce-I site. For more details on the specific primers used and the qPCRF
conditions please consult Appendix 6.4. We measured the disappearance of the
200 bp product that amplifies across the ISce-I break site in CHO33 and HT1080
cell lines (Figure 2.3). At six hours post infection, we observed more than 60%
ISce-I cutting in CHO33 cells and HT1080-1885 cells. Additionally, the human
HT1080-1885 cell line required a higher MOI for cutting as compared to the
CHO cells. These results have been repeated in other cell lines such as
HT1080-1904 (a HT1080 derivative containing an ISce-I substrate with
puromycin selection marker), with similar results (Appendix 6.4). Thus, these
results demonstrate that the Ad-ISce-I virus can be used as a tool to create
efficient DSB formation at a defined recognition site using qPCR. Rapid,
efficient, and reproducible cutting, with minimal side effects to cells is necessary
to study recruitment of proteins to DSB sites in response to a break. Ad-ISce-I
allows us to measure recruitment of repair proteins, via ChIP, within minutes of a
break occurring. Using this system we have detected early protein recruitment,
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studied the kinetics of recruitment, determined how close (how many bases or
kb) away from the break site the proteins have localized, and have asked
whether post-translational modifications affect protein recruitment to a break
site. Specifically, we have used this tool to study how Metnase affects
recruitment of proteins in the NHEJ pathway to a DSB site (Appendix 6.4).

A

B

Figure 6.7-3. Ad-ISce-I cuts ISce-I site rapidly and effectively.
(A) CHO-33 cells and (B) HT1080-1885 cells. Percent PCR
product remaining after infection by Ad-ISce-I at 100 or 1000 MOI, results
normalized to GAPDH (internal control). Representative of three
independent experiments, each done in triplicate, *p<0.05, **p<0.0001 (ttest).
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Next, we tested whether Ad-ISce-I infection would have an effect on cell
cycle progression, since many DNA damage response pathways are regulated
during the cell cycle. To test whether Ad-ISce-I affects the cell cycle we
conducted two experiments. The first was a Ad-ISce-I dose response experiment
to test if higher MOI would affect cell cycle. The second experiment was a time
course after adenovirus infection, to test whether the virus would have an effect
on cell cycle progression over time. We infected CHO33 and HT1080-1885
cells with Ad-ISce-I or Ad-βgal (an adenovirus containing the same DNA as AdISce-I, but carrying a β-gal gene instead of the ISce-I) control for a period of up
to 96 hours and stained cells for flow cytometry analysis as described in section
3.1. The results, shown in Figure 3-4, revealed that Ad-ISce-I infection did not
have a significant effect on cell cycle progression even at the highest viral titer of
1000 MOI in both cell lines tested. Therefore Ad-ISce-I is a useful tool for
studying DNA repair pathways since the infection by the virus alone does not
alter the cell cycle. However, these observations are limited to the cell lines
currently tested. When using this system in other cell lines, it will be important to
repeat these experiments and determine the optimal MOI to use for each cell
line.
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Figure 6.7-4. Ad-ISce-I does not affect cell cycle progression in human and
hamster cells.
Cell cycle profiles of human cell line HT1080-1885 (A) and Chinese
hamster ovary (CHO-33) (B) in response to 100 MOI Ad-ISce-I over time.
Results are representative of two different experiments, 0= control without virus,
I+ = Ad-ISce-I virus, I- = Ad-βgal (control).
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DNA Fiber Analysis
The DNA fiber analysis was developed originally by Parra and Windle
[161]. Merrick and colleagues [162] used this method to label ongoing replication
forks in vivo. I developed it further by adapting the procedure used by the
Aladjem lab [130] and Pommier laboratories [163]. DNA fiber analysis was used
to monitor DNA synthesis, by analyzing the incorporation of two 5-bromo-2deoxyuridine (BrdU) analogs, 5-iodo-2-deoxyuridine (IdU) and 5-chloro-2deoxyuridine (CldU), both of which are nucleoside analogs of thymidine. The
analogs are given sequentially, one is added, then a treatment that causes
replication fork stress or damage is given (typically 5 mM HU, which causes
nucleotide pools to be depleted), and then the other analog is added. Then the
DNA fibers are stretched as described in methods and the DNA is labeled with
primary and secondary-fluorescent antibodies against the analogs, and finally
visualized using a confocal microscope. The images obtained can be analyzed
in several ways. For example, one can measure the percentage of a type of
fiber, and determine whether forks were started, stopped, or continued after a
certain treatment that stresses replication forks (HU in this study). Fiber length
can also be measured using image analysis software (such as ImageJ), and the
nucleotide incorporation rate can be determined (see Fig 2.5). However, this
method has its limitations. Technically, the background fluorescence needs to be
eliminated by a series of optimization experiments. One should always include in
the experiments a control where each of the labeling dyes is given alone, in
order to assess background binding of the antibodies, tested by using IdU but
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only adding CldU antibodies and vice versa. Control experiments leaving out
primary or secondary antibodies should be done every time a new cell line is
being optimized and every time a new antibody batch is started. Additionally,
one should never incubate the antibodies together, especially the primary
antibodies, since they are both BrdU specific and can recognize both labeling
dyes (IdU and CldU). Technically, this method has the limitation that the labeling
is time dependent, thus a short fiber could indicate a slow incorporation rate or a
stalled fork. Additionally, this method does not allow for distinctions between a
stalled and a collapsed fork although in combination with other types of
experiments, such as H2AX foci formation, this information can be discerned.
Reagents
10 mM IdU
10 mM CIdU
PBS
70 % ethanol
100 % methanol
2.5 N HCl
5 % BSA in PBS
PBS-T (Triton 0.1 %)
DAPI (optional)
100 μM Thymidine
Mounting medium: PermaFluorTM aqueous mounting medium, self-sealing
(Thermoscientific cat #: TA-030-FM)
Positively charged slides (Daigger supperfrost/plus microslides, frosted cat#
G15978Z)
Microscope cover slides (VWR micro cover glass 24 x 50 mm cat# 48393 241)
SDS-Lysis Buffer:
0.5% SDS
200 mM Tri-HCl (pH 7.4)
50mM EDTA
Antibodies:
Mouse anti-BrdU (1:50) for IdU (BD Biosciences cat # 347580)
Rat anti-BrdU (1:100) for CldU (Accuratechemical cat # OBT0030)
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Day 1: (Perform the following steps in the dark or under low light)
1.

Grow cells in 10 mm culture dishes (or 6 well plates).

2.

Add 20 μM IdU (final concentration) to growth media, mix and incubate for
10 min at 37°C.

3.

Remove growth media and wash cells with PBS two times.

4.

Add 100 μM thymidine for 1 min to wash out the IdU before incubation
with the CldU nucleotide analog.

5.

Wash cells with PBS.

6.

Add complete growth medium.

7.

Add the treatment drug (i.e., 5 mM HU for 1-6 h or mock treat controls).

8.

Remove media and wash cells twice with PBS.

9.

Add 20 μM CIdU and incubate cells for 20 min at 37°C.

10.

Remove media and wash once with PBS.

11.

Harvest cells by trypsinization, spin cells at 1000 rpm (112 x g) for 5 min
at 4°C, wash once with PBS. Resuspend cells in 1.5 mL of PBS and
determine cell concentration using a hemocytometer.

12.

Transfer cells to a new eppendorf tube, spin down cells for 5 min at 5,000
rpm (2800 x g) at 4°C.

13.

Add PBS to make a final concentration of 1-2 x106 cell/mL. Cells may be
stored at 4°C overnight (do not store more than 2 days as the cells will
lyse and the DNA will not spread properly or at all).
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14.

Add 2 μL of cell sample to the top of the slide lying horizontally (not more
than 2,500 cells).

15.

Add 6 μL of SDS lysis buffer and immediately pipette mixture up, down 56 times, and stir to spread gently with the same tip (avoid creating
bubbles).

16.

Incubate for 5-8 min (3 min in low humidity climates).

17.

Tilt the slide at an angle such that the droplet reaches the bottom of the
slide in at least 30 sec. (figure 3-5).

18.

Cover slides with aluminum foil and air dry for 8 min at room temperature

19.

Fix with 3:1 methanol: acetic acid (prepared fresh) for 5 min.

20.

Dry the slides for 8 min and store in 70% EtOH at 4°C overnight
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Figure 6.7-5. Diagram of “dropping” DNA on a slide for Fiber Assay.
The DNA should be put on a slide toward one of the short edges. Raise
one end of the slide so that the DNA droplet can slide down and reach the
bottom in not less than 30 sec. The DNA should be spread down the middle of
the slide as much as possible as this will facilitate microscopy.
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Day 2: (Perform the following steps under low, indirect light)
1.

Incubate slides in 100% MeOH at room temperature for 5 min.

2.

Wash twice with PBS for 5 min each.

3.

Add 150 μL of 2.5 N HCl to each slide, cover with parafilm and incubate at
37°C in a wet box for 1 h (a wet box can be constructed from an empty
plastic pipette tip box with the bottom covered with a wet paper towel, this
prevents the slides from drying).

4.

Wash twice with PBS for 5 min each.

5.

Add 150 μL of 5% BSA to each slide, cover slides and incubate at 37°C in
a wet box for 15 min.

6.

Wash with PBS once.

7.

Add 150 μL mouse anti-BrdU (1:50 dil. in 0.5 % BSA in PBS) to detect
IdU, incubate at 37°C for 1 h.

8.

Wash slide three times with PBS-0.1 % Triton for 3-5 min, then rinse with
PBS.

9.

Add 150 μL goat anti-mouse Alexa 568 (1:100 in 0.5 % BSA in PBS);
incubate at 37°C for 1 h.

10.

Wash slide three times with PBS-0.1% Triton for 3-5 min each, then rinse
with PBS.

11.

Add 150 μL rat anti-BrdU (1:100, 0.5 % BSA in PBS) to detect CIdU;
incubate at 37°C for 1 h.

12.

Wash slide three times with PBS-0.1% Triton for 3-5 min, then rinse with
PBS.
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Add 150 μL donkey anti-rat Alexa 488 (1:100 in 0.5 % BSA in PBS) to

13.

detect CIdU; incubate at 37°C for 1 h.
14.

Wash slide three times with PBS-0.1% Triton for 3-5 min, then rinse with
PBS.
Stain slides with DAPI (125 μg/mL in PBS), incubate at R.T. for 1h (this is

15.

optional because DAPI staining is not always visible in the microscope).
16.

Wash twice with PBS for 5 min each.

17.

Add 25 μL of mounting medium (without DAPI) and cover with a cover
slip.

18.

Allow the slides to dry overnight in the dark and store at 4°C overnight or
until ready to visualize with a microscope (slides can be stored for ~6
months without significant degradation of the fluorescent signals).

19.

Image DNA fibers with a confocal microscope at 63x magnification (oil
immersion).

Notes:
1. It is very important that the protocol be followed mostly under dark or low
indirect light conditions because the labeling dyes are light sensitive.
2. Do not alter the order of antibody or incubation times because both
antibodies used are BrdU specific and can recognize both dyes. The
order specified in this protocols gives optimal results.
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3. Do not spread more than 2,500 cells per slide because more cells means
more DNA and that will result in fibers grouping and spreading together
and will not be quantifiable.
4. At step 13 of Day 1, cells can only be stored overnight, not for several
days as the cell will lyse and no fibers can be obtained.
5. DNA fibers are best visualized with a confocal microscope with 40x or 63x
magnification, 100x magnification is not required or necessary.
6. Optimize microscope settings to minimize bleed-through and to maximize
resolution of the fibers. Consult microscope manuals to learn how to do
optimization.
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Figure 6.7-6. Diagram of DNA fiber technique and example of a result.
(A) Diagram of the time course of nucleotide analog labeling. (B) Confocal
microscopy image examples of DNA fibers. An ongoing fork is a fork that started
incorporating analogs during the first step of the process (IdU) and can be seen
as a fiber with a combination of red, green, and yellow (overlap of both analogs).
A new fork is seen as only green fibers because it only incorporated the second
analog (CldU). A stopped fork is seen as only red, as it incorporated the first
analog (IdU), but failed to incorporate the second (CldU). One μm in fiber length
is the equivalent of 2 kb of DNA; therefore, the DNA replication fork rate can be
calculated by converting the length of a fiber to kilobases and dividing that
number by the number of minutes the DNA was exposed to the labeling analog,
providing a rate in kb/min.
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